Clinical Study Protocol -5.[ADDRESS_1283378] Supportive Care in 
Subjects Hospi[INVESTIGATOR_21391] -19
Sponsor:
Acerta Pharma B.V., a Dutch limited liabilit y company, whose registered office is at 
Kloosterstraat 9, 5349 AB, Oss, The Netherlands, a member of the [COMPANY_008] group 
(“Co mpany”)
IND Number 149513
Clinical Study Protocol -5.0 [COMPANY_008]
Acalabrutinib -D822 FC00003
CONFIDENTIAL AND PROPRIETARY 2of 103PROTOCOL AMENDMENT S UMMARY OF CHANGES TABLE
DOCUMENT HISTORY
Document Date
Amendment 4 (Version 5.0) 24Jul2020
Amendment 3 (Version 4.0) 23Jun2020
Amendment 2 (Version 3.0) 13May2020
Amendment 1 (Version 2.0) 08May2020 
Original Protocol (Version 1.0) 01May2020
Amendment 4 (24Jul2020) 
The overall rationale for this amendment was to address feedback from study  sites that are 
managing pat ient care duri ng the COVID -19 pandemic .
In addit ion to the am endment changes summarized below, a few minor errors and ty pos were 
corrected.
Section number and 
nameDescription of change Brief rationaleSubstantial/ 
non-substantial
1.1 Schedule of 
Activities (Table 1 and 
Table 2)Rem oved Day 1 column from 
both Tables 1 and 2. Made 
changes to “Daily until hospi[INVESTIGATOR_7954]” column to adjust for 
this change.Clarification Non-substantial
1.1 Schedule of 
Activities (Table 1)Substantial
1.1 Schedule of 
Activities (Table 2)Substantial
1.1 Schedule of 
Activities (Table 1 and 
Table 2),
8.3 On -study 
ProceduresAdded nasal swab sample 
collection for SARS -CoV -2 viral 
load/viral sheddingTo clarify method of sample 
collection for SARS -CoV -2 
viral load/viral sheddingSubstantial
CCI
Clinical Study Protocol -5.0 [COMPANY_008]
Acalabrutinib -D822FC00003
CONFIDENTIAL AND PROPRIETARY 3of 103Section number and 
nameDescription of change Brief rationaleSubstantial/ 
non-substantial
1.1 Schedule of 
Activities (Table 1),
9.6.3 Pharmacokinetic 
and Pharmacodynamic 
Analy sesAdded footnote t to Table 1 and 
text to Section 9.6.3 to indicate 
that PK assessments will be 
conducted in up to 15evaluable 
subjects and PD assessments in 
up to 15evaluable subjects 
randomize d to Arm 1 
(acalabrutinib + BSC)Assessment in up to 
15evaluable subjects each are
considered adequate to 
characterize the PK /active 
metabolite and PD, 
respectively, ofacalab rutinib 
in the COVID -19populationNon-substantial
1.2 Synopsis,
6.1.1 Dosing a nd 
Duration of Treatment,
[IP_ADDRESS] Drug -drug 
Interactio ns,
6.5.4 Acalabrutinib 
Drug -drug Interaction 
Guidance in the 
Presence of Life -
threatening COVID -19 
Infection,
[IP_ADDRESS] Active 
Substances That May 
Decrease Acalabrutinib 
Plasma Co ncentrationsFor subjects not on PPIs, 
removed volume (240 mL) of 
water and just stated that it 
should be taken with water. For 
subjects who are on PPIs, 
changed volume of COCA -
COLA from 240 mL to “at least 
100mL”. Based on in -vitro data, 
administering acalabrutinib 
100 mg o ral capsules (in the 
presence of PPIs) with at least 
a [ADDRESS_1283379] of PPIs 
on acalab rutinib PK/PDNon-substantial
1.2 Synopsis,
4.4 Internal DMCAdded text to indicate that the 
iDMC wi ll review safety and 
efficacy data. In addition, the 
iDMC may support any health 
autho rity interactions o r internal 
discussions based on their 
review, and the study team will 
remain blinded to the data that 
the iDMC will review .For transparency and to 
preserve the trial integritySubstantial
5.2 Exclusion Criteria Rem oved thecutoffs for oxygen 
flow rates from Exclusion 
Criterio n 1and indicated that 
subjects should be considered 
for eligibility in part based on 
their ability to swallow pi[INVESTIGATOR_913309] -5.0 [COMPANY_008]
Acalabrutinib -D822FC00003
CONFIDENTIAL AND PROPRIETARY 4of 103Section number and 
nameDescription of change Brief rationaleSubstantial/ 
non-substantial
Added an exception to Exclusion 
Criterio n [ADDRESS_1283380] 
and/o r ALT can be up to 5 ×
ULN if considered due to 
underlying COVID -19, but 
cannot be associated with 
concurrent elevated bilirubin (up 
to 2×ULN)Hepatotoxicity and ALT/AST 
are not currently adverse drug 
reactions for acalabrutinib and 
there is evidence for 
ALT/AST increases associated 
with COVID -19 (Cai et al 
2020 , Guan et al 2020 )Substantial
8.1 Screening 
Assessments,
8.1.1 Informed ConsentMoved second paragraph under 
Section 8.1.1 to Section 8.1Paragraph relates to all 
screening visitsNon-substantial
9.6. Statistical Analyses Added a description of the 
timing of the primary analysis of 
thestudy and the updated 
analy sisFor clarity Non-substantial
ALT = alanine aminotransferase; AST = aspartate aminotransferase; BSC = best supportive care; COVID -19 = coronavirus 
disease 2019; iDMC = internal Data Monitoring Committee; PD=pharmacodynamic s; PK =pharmacokinetics; PPI = proton -
pump inhibitor; SARS -CoV-2 = severe acute respi[INVESTIGATOR_6507] 2; ULN =upper limit of normal .
Clinical Study Protocol -5.[ADDRESS_1283381] ivities (SoA) ................................ ................................ ............... 9
1.2 Synopsis ................................ ................................ ................................ ........... 17
1.3 Schema ................................ ................................ ................................ ............. 22
2. INTRODUCTION ................................ ................................ ............................ 24
2.1 Background and Study  Rationale ................................ ................................ ......24
2.2 Benefit/Risk Assessment ................................ ................................ ................... 25
3. OBJECTIVES AND ENDPO INTS ................................ ................................ ...26
4. STUDY DESIGN ................................ ................................ ............................. 28
4.1 Overall Design ................................ ................................ ................................ ..28
4.2 ScientificRationale f or Study  Design ................................ ................................ 29
4.3 Justification for Dose ................................ ................................ ........................ 29
4.4 Internal DMC ................................ ................................ ................................ ....30
4.5 End of Study  Definit ion................................ ................................ .................... 30
5. STUDY POPULATION ................................ ................................ ................... 31
5.1 Inclusio n Cri teria................................ ................................ .............................. 31
5.2 Exclusio n Cri teria................................ ................................ ............................. 31
5.3 Screen Failures ................................ ................................ ................................ .34
6. STUDY TREATMENTS ................................ ................................ .................. 34
6.1 Treatments Administered ................................ ................................ .................. 34
6.1.1 Dosing and Duration of Treatment ................................ ................................ ....34
6.1.2 Missed Dosing Windows and Doses ................................ ................................ ..34
6.1.3 Speci al Considerati ons................................ ................................ ...................... 35
[IP_ADDRESS] Drug -drug Interactions ................................ ................................ ...................... 35
[IP_ADDRESS] Subjects Wit h Respi[INVESTIGATOR_913310] ................. 35
[IP_ADDRESS] Subjects No Longer Able to Swallow Pi[INVESTIGATOR_3353] ................................ ........................ 35
[IP_ADDRESS] Vomit ing After Acalabrutinib Treat ment................................ ........................... 36
[IP_ADDRESS] Discharged From Hospi[INVESTIGATOR_913311]................................ .36
6.2 Acalabrut inib Preparat ion/Handling/Storage/Accountabilit y............................. 36
6.3 Measures to Minimise Bias: Rando misat ion and Blinding ................................ .[ADDRESS_1283382] Enrollment and Rando mizat ion................................ ............................. 37
[IP_ADDRESS] Procedures for Handling Incorrectly Enro lled or Rando mized Subjects ............. 37
[IP_ADDRESS] Methods for Assigning Treatment Groups ................................ ......................... 38
[IP_ADDRESS] Methods for Ensuring Blinding ................................ ................................ ......... [ADDRESS_1283383] ion................................ ................................ ......................... 40
[IP_ADDRESS] Active Substances That May Increase Acalabrut inib Plasma Concentrations .....40
[IP_ADDRESS] Active Substances That May Decrease Acalabrutinib Plasma Concentrations ....[ADDRESS_1283384] Imaging, Electrocardiogram, and 
Echocardi ogram ................................ ................................ ................................ 49
8.1.6 Vital Signs................................ ................................ ................................ ........ 50
8.1.7 Urine or S erum Pregnancy ................................ ................................ ................ 50
8.1.8 Laboratory  Tests ................................ ................................ ............................... 50
8.2 Concomitant Medications ................................ ................................ ................. 51
8.3 On-study  Procedures ................................ ................................ ......................... 51
8.4 Clinic al Assessments During Hospi[INVESTIGATOR_059] ................................ .................... 53
8.4.1 Oxygen Treatments and Vent ilator Use ................................ ............................. 53
8.4.2 Modified Sequent ial Organ Failure Assessment (SOFA) Scores ........................ [ADDRESS_1283385] ing AE and SAE Informat ion................ 55
8.6.3 Follow-up of  AEs and SAEs ................................ ................................ ............. 55
8.6.4 Adverse Event Data Collection ................................ ................................ ......... 56
8.6.5 Causalit y Collection................................ ................................ .......................... 56
8.6.6 Adverse Events Based on Signs and Symptoms ................................ ................ 57
8.6.7 Adverse Events Based on Examinat ions and Tests ................................ ............ 57
8.6.8 Hy’s Law ................................ ................................ ................................ .......... [ADDRESS_1283386] ................................ ................................ ....58
8.7 Safety Reporting and Medical Management ................................ ...................... 59
8.7.1 Reporting of Serious Adverse Events ................................ ................................ 59
8.7.2 Pregnancy ................................ ................................ ................................ ......... 60
[IP_ADDRESS] Maternal Exposure ................................ ................................ ............................ 60
[IP_ADDRESS] Paternal  Exposure ................................ ................................ ............................. [ADDRESS_1283387] ivities -Arm 1 (Acalabrutinib + BSC) ............................. [ADDRESS_1283388] ivities -Arm 2 (BSC Only) ................................ ............. [ADDRESS_1283389] ives and Endpo ints................................ ........................... 26
Clinical Study Protocol -5.0 [COMPANY_008]
Acalabrutinib -D822FC00003
CONFIDENTIAL AND PROPRIETARY 8of 103Table 4 Acalabrut inib Use with Moderate CYP3A Inhibitors and Gastric Acid 
Reducing Agents ................................ ................................ ...................... 40
Table 5 Risks Associated with Ac alabrut inib Monotherapy in Subjects Wit h 
Hem atologic Malignancies (N = 1040) ................................ ..................... [ADDRESS_1283390] ious 
Substances ................................ ................................ ............................... 81
Table 8 CYP3A Inhibitors ................................ ................................ .................... 87
Table 9 CYP3A Inducers ................................ ................................ ...................... 88
Table 10 Other Drugs Needing Addit ional Considerat ions................................ ......88
Table 11 Highly Effective Methods of Contraception (<1% Failure Rate) ............... [ADDRESS_1283391] OF APPENDICES
Appendix A Regulatory , Ethical  and Study  Oversight Considerations .......................... 70
Appendix B Adverse Event Definit ions and Addit ional Safet y Inform ation................. 75
Appendix C Handling of Human Bio logical  Samples ................................ .................. 79
Appendix D Actions Required in Cases of Increases in Liver Biochemistry  and 
Evaluat ion of Hy’s Law ................................ ................................ ........... 82
Appendix E Examples of Coadministered Drugs That Need Addit ional Considerat ion87
Appendix F Contraception Requirements ................................ ................................ ....89
Appendix G Child -Pugh Score ................................ ................................ ..................... 91
Appendix H Abbreviat ions................................ ................................ .......................... 92
Appendix I Protocol  Amendment Hi story ................................ ................................ ...95
Clinical Study Protocol -5.0 [COMPANY_008]
Acalabrutinib -D822FC00003
CONFIDENTIAL AND PROPRIETARY 9of 1031. PROTOCOL SUMMARY
1.1 Schedule of Activities (SoA)
The SoA sfor Arm 1 (acal abrutinib + best supportive care [BSC]) and Arm 2 (BSC only) are 
presented in Table 1and Table 2, respectively .
Clinical Study Protocol -5.0 [COMPANY_008]
Acalabrutinib -D822FC00003
CONFIDENTIAL AND PROPRIETARY 10of 103Table 1 Schedule of Activities -Arm 1 (Acalabrutinib + BSC)
AssessmentsScreening
(Day -3 to 
Day -1 l)Daily until hospi[INVESTIGATOR_913312] 10 or 
discharge hDay 14
(±2 days) 
after 
randomi -
zationDay 28
(±3 days) 
after 
randomi -
zationSafety FU
28 (±3) days 
after last dose 
of acala -
brutinib iLong -term 
FU 90 (±7) 
days after 
randomi -
zation i,jCSP 
section
Informed consent X 8.1.1
Demography X 8.1.2
Determine eligibility X 5.1, 5.2
Medical history and COVID -19 
epi[INVESTIGATOR_913313] 8.1.4
Physical examination (symptom 
driven, including lung 
auscultation, height, weight)X 8.1.[ADDRESS_1283392] imaging X rAs clinically indicated 8.1.5 , 8.3
Electrocardiogram X lAs clinically indicated X 8.1.5 , 8.3
EchocardiogramAs clinically 
indicatedAs clinically indicated 8.1.5 , 8.3
Vital signs (blood pressure, 
respi[INVESTIGATOR_697], oximetry, pulse 
and body temperature)XsX X X X 8.1.6 , 8.3
Local laboratory assessments:
Urine or serum pregnancy test 
(for WOCBP only)X X X 8.1.7 , 8.3
Hematology bX X X X X X 8.1.8 , 8.3
Serum or plasma chemistry cX X X X X X 8.1.8 , 8.3
Arterial blood gases (if 
available) nX X X X8.1.6 , 8.1.8 , 
8.3, 8.4.1
Hepatitis B and C testing dX As clinically indicatedAs clinically 
indicated6.6.3 ,8.1.8 , 
8.3
Serum ferritin mXqod 
(starting from Day 1)X X X 8.1.8 , 8.3
Fibrinogen mX qod 8.1.8 , 8.3
PT, aPTT, and INR mX qod 8.1.8 , 8.3
Clinical Study Protocol -5.0 [COMPANY_008]
Acalabrutinib -D822FC00003
CONFIDENTIAL AND PROPRIETARY 11of 103Table 1 Schedule of Activities -Arm 1 (Acalabrutinib + BSC)
AssessmentsScreening
(Day -3 to 
Day -1 l)Daily until hospi[INVESTIGATOR_913312] 10 or 
discharge hDay 14
(±2 days) 
after 
randomi -
zationDay 28
(±3 days) 
after 
randomi -
zationSafety FU
28 (±3) days 
after last dose 
of acala -
brutinib iLong -term 
FU 90 (±7) 
days after 
randomi -
zation i,jCSP 
section
D-dimer mX qod X X 8.1.8 , 8.3
CRP X X X X X 8.1.8 , 8.3
Procalcitonin (if available) mX qod X X 8.1.8, 8.3
Cardiac troponin ImX Day 5 X 8.1.8 , 8.3
SARS -CoV -2 RT -PCR virus 
testing for eligibility eWithin 
7 day s prior 
to randomi -
zation8.1.8 , 5.1
Clinical assessments As applicable until hospi[INVESTIGATOR_2345] 8.4
9-point ordinal scale X X X X 8.8.1
Central laboratory assessments q
Correlative samples a,oDays 1a, 3,and 7 X X X - 8.3
Immunophenotypi[INVESTIGATOR_007] a,gDays 1a, 3,and 7 X X X 8.3
Serum and nasal swab samples 
for SARS -CoV -2 viral 
load/viral shedding aDays 1a, 3,and 7 X X X 8.3
Acalabrutinib PKp,t0.5 and 2 hours 
postdose on Day 3;
1 and 4 hours postdose 
on Day 78.3
CCI
Clinical Study Protocol -5.0 [COMPANY_008]
Acalabrutinib -D822FC00003
CONFIDENTIAL AND PROPRIETARY 12of 103Table 1 Schedule of Activities -Arm 1 (Acalabrutinib + BSC)
AssessmentsScreening
(Day -3 to 
Day -1 l)Daily until hospi[INVESTIGATOR_913312] 10 or 
discharge hDay 14
(±2 days) 
after 
randomi -
zationDay 28
(±3 days) 
after 
randomi -
zationSafety FU
28 (±3) days 
after last dose 
of acala -
brutinib iLong -term 
FU 90 (±7) 
days after 
randomi -
zation i,jCSP 
section
Acalabrutinib administrationThe first dose of 
acalabrutinib should 
be administered 
within 6 hours of 
randomization
100mg bid (q12h) × 
10 days (maximum)6.1
Adverse events XkX X X X Xj8.6
Concomitant medications X X X X X Xj8.2
Survival status X X XjXj4.5
anti-HBc = hepatitis B core antibody; aPTT = activated partial thromboplastin time, bid = twice daily; BSC = best supportive care; CD = cluster of differentiation; 
CRP = C-reactive protein; CT=computed tomography; ECG = electrocardiogram; FU = follow -up; COVID -19 = coronavirus disease 2019; CSP = Clinical Study Protocol; 
HBsAg =hepatitis B surface antigen; HCV =hepatitis C virus; ICF = Informed Consent Form; ICU = intensive care unit; INR = international normalized ratio; 
PBMC =peripheral blood mononuclear cell; PD =pharmacodynamics; PK = pharmacokinetics; PT = prothrombin time; q12h = every 12 hours; qod = every other day; 
RT-PCR =reverse transcriptase -polymerase chain reaction; SAE = serious adverse event; SARS -CoV-2 = severe acute respi[INVESTIGATOR_6507] 2; WOCBP = women of 
childbearing potential.
aPredose.
bHematology: complete blood count with differential includes, but not limited to white blood cell count, hemoglobin, plate let count, absolute neutrophil count (ANC) or 
percentage, red blood cell count, absolute monocyte count or percentage, and absolute lymphocyte count (ALC) or percentage. 
cSerum or plasma chemistry: albumin, alkaline phosphatase, alanine transaminase (ALT), aspartate aminotransferase (AST), bicarbonate, blood urea nitrogen (BUN), 
calcium, chloride, creatinine, glucose, lactate dehydrogenase (LDH), magnesium, phosphate/phosphorus, potassium, sodium, tota l bilirubin (direct and indirect bilirubin, if 
available ), total protein and uric acid. 
dHepatitis serology must include, at a minimum, HBsAg, anti -HBc, and HCV antibody. If additional hepatitis serology is collected per institutional guidelines, it should be 
recorded in the database. Additional testing informa tion is provided in Section 6.6.[ADDRESS_1283393] be confirmed according to the World Heal th Organization criteria (including positive nucleic acid test of any specimen [eg, respi[INVESTIGATOR_696], blood, 
urine, stool, or other bodily fluid]) within [ADDRESS_1283394] has already been documented within 7 days prior to randomization, no need to repeat the 
testing again.
f
gFlow cytometry testing of peripheral blood will include, but is not limited to, CD3+, CD4+, CD8+, CD14+, CD19+, and CD16 +/56+ cells.
hIf a subject is discharged prior to Day 7, he/she needs to visit the site for an assessment 2 to 4 days after discharge. Asse ssments should match those for Day 10.
iTelemedicine is recommended for capturing adverse events concomitant medication s, and survival. Safety laboratory tests can be done at the hospi[INVESTIGATOR_6879] a local laboratory 
provided the results are ultimately captured in the clinical database for the study.
jAll subjects will be followed for survival for 90 (± 7) days.
CCI
Clinical Study Protocol -5.0 [COMPANY_008]
Acalabrutinib -D822FC00003
CONFIDENTIAL AND PROPRIETARY 13of 103Table 1 Schedule of Activities -Arm 1 (Acalabrutinib + BSC)
AssessmentsScreening
(Day -3 to 
Day -1 l)Daily until hospi[INVESTIGATOR_913312] 10 or 
discharge hDay 14
(±2 days) 
after 
randomi -
zationDay 28
(±3 days) 
after 
randomi -
zationSafety FU
28 (±3) days 
after last dose 
of acala -
brutinib iLong -term 
FU 90 (±7) 
days after 
randomi -
zation i,jCSP 
section
kAfter signing the ICF, but prior to randomization, only SAEs should be reported (see Section 8.6.2 ).
lScreening can be performed within 1 to 3 days p rior to dosing, depending on the local requirements for laboratory turn -around times; ECG can be collected at any time 
during this screening window.
mSerum ferritin, fibrinogen, PT, aPTT, INR, D -dimer, procalcitonin, and cardiac troponin I should be perform ed more frequently if clinically indicated.
nArterial gases should be collected from subjects if the sample is easily accessible and the procedure will not be painful to subjects (ie, subject is in ICU or has arterial port). 
All available data from the arte rial gases should be entered into the database. If the collection of arterial gases is not clinically indicated, the test sho uld not be performed.
o
pAll blood samples for PK assessment (ie, 0.5, 1, 2, and 4 hours postdose) can also be collected during a single visit on Day 3 or after.
qFor all central laboratory assessments, sample collection windows of ± [ADDRESS_1283395], or any other appropriate means to confirm pneumonia prior to or upon 
hospi[INVESTIGATOR_059] (within 7 days of randomization).
sDuring screening, vital signs s hould be collected as close as possible to randomization on Day 1. If more than one value is obtained for vital signs during screening, the value 
closest to randomization should be used.
tPK assessments will be conducted in up to 15 evaluable subjects and PDassessments in up to 15evaluable subjects randomized to Arm 1 (acalabrutinib + BSC) .
CCI
Clinical Study Protocol -5.0 [COMPANY_008]
Acalabrutinib -D822FC00003
CONFIDENTIAL AND PROPRIETARY 14of 103Table 2 Schedule of Activities -Arm 2 (BSC Only)
AssessmentsScreening
(Day -3 to 
Day -1 l)Daily until hospi[INVESTIGATOR_913312] 10 or 
discharge hDay 14
(±2 days) 
after 
randomi -
zationDay 28
(±3 days) 
after 
randomi -
zationSafety FU
38 (±3) days 
after randomi -
zation iLong -term 
FU 90 (±7) 
days after 
randomi -
zation i,jCSP 
section
Informed consent X 8.1.1
Demography X 8.1.2
Determine eligibility X 5.1, 5.2
Medical history and COVID -19 
epi[INVESTIGATOR_913313] 8.1.4
Physical examination (symptom 
driven, including lung auscultation, 
height, weight)X 8.1.[ADDRESS_1283396] imaging X qAs clinically 
indicated8.1.5 , 8.3
Electrocardiogram X lAs clinically 
indicatedX 8.1.5 , 8.3
EchocardiogramAs clinically 
indicatedAs clinically 
indicated8.1.5 , 8.3
Vital signs (blood pressure, 
respi[INVESTIGATOR_697], oximetry, pulse 
and body temperature)XrX X X X 8.1.6 , 8.3
Local laboratory assessments:
Urine or serum pregnancy test 
(for WOCBP only)X X X 8.1.7 , 8.3
Hematology bX X X X X X 8.1.8 , 8.3
Serum or plasma chemistry cX X X X X X 8.1.8 , 8.3
Arterial blood gases (if 
available) nX X X X8.1.6 , 8.1.8 , 
8.3, 8.4.1
Hepatitis B and C testing dXAs clinically 
indicatedAs clinically 
indicated6.6.3 ,8.1.8 , 
8.3
Serum ferritin mXqod 
(starting from Day 1)X X X 8.1.8 , 8.3
Fibrinogen mX qod 8.1.8 , 8.3
Clinical Study Protocol -5.0 [COMPANY_008]
Acalabrutinib -D822FC00003
CONFIDENTIAL AND PROPRIETARY 15of 103Table 2 Schedule of Activities -Arm 2 (BSC Only)
AssessmentsScreening
(Day -3 to 
Day -1 l)Daily until hospi[INVESTIGATOR_913312] 10 or 
discharge hDay 14
(±2 days) 
after 
randomi -
zationDay 28
(±3 days) 
after 
randomi -
zationSafety FU
38 (±3) days 
after randomi -
zation iLong -term 
FU 90 (±7) 
days after 
randomi -
zation i,jCSP 
section
PT, aPTT, and INR mX qod 8.1.8 , 8.3
D-dimer mX qod X X 8.1.8 , 8.3
CRP X X X X X 8.1.8 , 8.3
Procalcitonin (if available) mX qod X X 8.1.8 , 8.3
Cardiac troponin ImX Day 5 X 8.1.8 , 8.3
SARS -CoV -2 RT -PCR virus 
testing for eligibility eWithin 
7 day s prior 
to rando mi-
zation8.1.8 , 5.1
Clinical assessments As applicable until hospi[INVESTIGATOR_2345] 8.4
9-point ordinal scale X X X X 8.8.1
Central laboratory assessments p
Correlative samples a,oDays 1a, 3,and 7 X X X - 8.3
Immunophenotypi[INVESTIGATOR_007] a,gDays 1a, 3,and 7 X X X 8.3
Serum and nasal swab samples 
for SARS -CoV -2 viral load/viral 
shedding aDays 1a, 3,and 7 X X X 8.3
Adverse events XkX X X X Xj 8.6
Concomitant medications X X X X X Xj 8.2
Survival status X X XjXj4.5
anti-HBc = hepatitis B core antibody; aPTT = activated partial thromboplastin time, BSC = best supportive care; CD = cluster of di fferentiation; CT =computed tomography; 
ECG = electrocardiogram; FU = follow -up; COVID -19 = coronavirus disease 2019; CRP = C -reactive protein; CSP = Clinical Study Protocol; HBsAg =hepatitis B surface 
antigen; HCV = hepatitis C virus; ICF = Informed Consent Form; ICU = intensive care unit; INR = int ernational normalized ratio; PBMC = peripheral blood mononuclear cell; 
PT= prothrombin time; qod =every other day; RT- PCR =reverse transcriptase -polymerase chain reaction; SAE = serious adverse event; SARS -CoV-2 = severe acute respi[INVESTIGATOR_597211] 2; WOCBP = women of childbearing potential.
aPredose.
CCI
Clinical Study Protocol -5.0 [COMPANY_008]
Acalabrutinib -D822FC00003
CONFIDENTIAL AND PROPRIETARY 16of 103Table 2 Schedule of Activities -Arm 2 (BSC Only)
AssessmentsScreening
(Day -3 to 
Day -1 l)Daily until hospi[INVESTIGATOR_913312] 10 or 
discharge hDay 14
(±2 days) 
after 
randomi -
zationDay 28
(±3 days) 
after 
randomi -
zationSafety FU
38 (±3) days 
after randomi -
zation iLong -term 
FU 90 (±7) 
days after 
randomi -
zation i,jCSP 
section
bHematology: complete blood count with differential includes, but not limited to white blood cell count, hemoglobin, platelet count, absolute neutrophil count (ANC) or 
percentage, red blood cell count, absolute monocyte count or percentage, and absolute lym phocy te count (ALC) or percentage. 
cSerum or plasma chemistry: albumin, alkaline phosphatase, alanine transaminase (ALT), aspartate aminotransferase (AST), bicar bonate, blood urea nitrogen (BUN), 
calcium, chloride, creatinine, glucose, lactate dehydrogenas e (LDH), magnesium, phosphate/phosphorus, potassium, sodium, total bilirubin (direct and indirect bilirubin, if 
available), total protein and uric acid. 
dHepatitis serology must include, at a minimum, HBsAg, anti -HBc, and HCV antibody. If additional hepati tis serology is collected per institutional guidelines, it should be 
recorded in the database. Additional testing information is provided in Section 6.6.[ADDRESS_1283397] be confirmed according to the World Health Organization criteria (including positive nucleic acid test of any specimen [eg, respi[INVESTIGATOR_696], blood, 
urine, stool, or other bodily fluid]) within [ADDRESS_1283398] has already been documented within 7 days prior to randomization, no need to repeat the 
testing again.
f
gFlow cytometry testing of peripheral blood will include, but is not limited to, CD3+, CD4+, CD8+, CD14+, CD19+, and CD16+/56+ cells.
hIf a subject is discharged prior to Day 7, h e/she needs to visit the site for an assessment 2 to 4 days after discharge. Assessments should match those for Day 10.
iTelemedicine is recommended for capturing adverse events concomitant medications, and survival. Safety laboratory tests can b e done at t he hospi[INVESTIGATOR_6879] a local laboratory 
provided the results are ultimately captured in the clinical database for the study.
jAll subjects will be followed for survival for 90 (± 7) days.
kAfter signing the ICF, but prior to randomization, only SAEs should be repo rted (see Section 8.6.2 ).
lScreening can be performed within 1 to 3 days prior to dosing, depending on the local requirements for laboratory turn -around times; ECG can be collected at any time 
during this screening window.
mSerum ferritin, fibrinogen, PT, aPTT, INR, D -dimer, procalcitonin, and cardiac troponin I should be performed more frequently if clinically indicated.
nArterial gases should be colle cted from subjects if the sample is easily accessible and the procedure will not be painful to subjects (ie, subject is in IC U or has arterial port). 
All available data from the arterial gases should be entered into the database. If the collection of arter ial gases is not clinically indicated, the test should not be performed.
o
pFor all central laboratory assessments, sample collection windows of ± [ADDRESS_1283399], or any other appropriate means to confirm pneumonia prior to or upon 
hospi[INVESTIGATOR_059] (within 7 days of ra ndomization).
rDuring screening, vital signs should be collected as close as possible to randomization on Day 1. If more than one value is obtained for vital signs during screening, the value 
closest to randomization should be used.
CCI
CCI
Clinical Study Protocol -5.0 [COMPANY_008]
Acalabrutinib -D822FC00003
CONFIDENTIAL AND PROPRIETARY 17of 1031.2 Synopsis
International Co-ordinating Investigators:
Wyndham Wilson, MD PhD
Center for Cancer Research
National Cancer Inst itute
Building 10, Room 12C -442
Bethesda, MD [ZIP_CODE]
Protocol Title: 
A Phase [ADDRESS_1283400] Supportive Care in Subjects Hospi[INVESTIGATOR_215444] h COVID -19
Rationale: 
Coronavirus disease 2019 (COVID -19) is a new pandemic disease caused by [CONTACT_913362] [INVESTIGATOR_584155] 2 (SARS -CoV -2). Most COVID -19 cases (~80%) are mild 
respi [INVESTIGATOR_913314]. However, the some require hospi[INVESTIGATOR_059] (most ly due to pneumonia) 
and can progress quickly to severe acute lung injury and acute respi[INVESTIGATOR_433260] 
(ARDS) (Huang et al 2020 , Wu and McGoogan 2020 , Zhou et al 2020 ), whi ch is associated 
with high m ortali ty. A vi ral-induced cy tokine storm  or “hyperimmune response” is 
hypothesized to be a major pathogenic mechanism of ARDS in these pat ients through 
modulat ion of pulmo nary macrophages and dendr itic cells (Channappanavar et al 2016 , 
Huang et al 2005 , Wong et al 2004 , Yoshikawa et al 2009 )and/or neutrophils (Herol d et al  
2015 ). Putative inflammatory  mediators include interl eukin ( IL)-1β, IL-6, IL -8, IL -10,tumor 
necrosis factor alpha ( TNF α),and monocy te chemoattractant protein -1 (MCP -1)(Chen et al 
2020 , Herold et al 2015 , Yoshikawa et al 2009 ).
Bruton ’styrosine kinase (Btk) is a Tec family  non-receptor protein kinase, expressed in B 
cells, myelo id cells, osteoclasts, mast cells and platelets. The function o f Btk in signaling 
pathways activated by  [CONTACT_913363] B -cell receptor h as been well established (Buggy  
and Elias 2012 ). Btk is also invo lved in the fo llowing bio logic processes: Fc gamma receptor 
signaling in myelo id cells, mast cell degranulat ion, osteoclast different iation, and signaling 
through Toll -like receptors (TLRs) in macrophages and neutrophils. Btk inhibit ion is 
associ ated wi th a decrease in proinflammatory  cytokines in patients with hematologic 
malignancies.
Acalabrut inib is a covalent Btk inhibitor with greater select ivity and better physiochemical 
properties than ibrut inib and other Btk inhibitors currently i n devel opment. Acalabrutinib is 
currently approved in the [LOCATION_002] for the treatment of patients with mant le cell 
lympho ma or chronic lymphocyt ic leukemia/small lymphocyt ic lympho ma [Calquence® 
prescribing information]. Patients with hematologic malig nancies treated with acalabrut inib 
Clinical Study Protocol -5.[ADDRESS_1283401] shown statistically  significant decreases in the following cy tokines: TNFα (p<0.001), 
IL-10 (p<0.001), and MCP -1 (p<0.01) (By[CONTACT_26753] 2016 )and IL -6 (p<0.05) (data on file). 
Decreasin g these immuno modulating cytokines in patients with COVID -[ADDRESS_1283402] itutes of Healt h (Roschewski 2020 ). Similarly, other BTK inhibitors have shown 
promise in COVID -19 patients with hematologic malignancies (Thibaud et al 2020 , Treon et 
al 2020 ).
The purpose of this Phase [ADDRESS_1283403] supportive care (BSC) for su bjects with life -threatening COVID -19 
symptoms.
Objectives and Endpoints:
Primary Objective s Primary Endpoints/Variables
To evaluate the safety of acalabrutinib in 
subjects with COVID -19 when administered 
with BSC
To evaluate the efficacy of adding 
acalabrutinib to BSC for the treatment of 
COVID -19Safety
Type, frequency, severity, and relationship to 
study treatment of any treatment -emer gent 
adverse events (TEAEs) or abnormalities of 
laboratory tests, serious adverse events 
(SAEs), or adverse events (AEs) leading to 
discontinuation of study treatment.
Efficacy
Proportion of subjects alive and free of 
respi[INVESTIGATOR_226284] 28
For the purpose of this study, respi[INVESTIGATOR_913315]:
oEndotracheal intubation and mechanical 
ventilation
oOxygen delivered by [CONTACT_5019] -flow nasal 
cannula (heated, humidified, oxygen 
delivered via reinforced nasal cannula at 
flow rates >2 0L/min with fraction of 
delivered oxygen ≥0.5)
oNoninvasive positive pressure ventilation 
or continuous positive airway pressure 
oExtracorporeal membrane oxygenation 
Secondary Efficacy Objective s Secondary Efficacy Endpoints/Variables
To evaluate the efficacy of adding acalabrutinib 
to BSC for the treatment of COVID -19Proportion of subjects alive and free of 
respi[INVESTIGATOR_1399] (defined above) at Day 14
Clinical Study Protocol -5.0 [COMPANY_008]
Acalabrutinib -D822FC00003
CONFIDENTIAL AND PROPRIETARY 19of 103Percent c hange from baseline in C -reactive 
protein ( CRP; time frame: baseline, Days 3, 
5, 7, 10 , 14, 28)
Change from baseline in ferritin (time frame: 
baseline, Days 3, 5, 7, 10 , 14, 28 )
Change from baseline in absolute 
lymphocyte counts (time frame: baseline, 
Days 3, 5, 7, 10 , 14, 28 )
All-cause mortality at Day 90
Proportion of subjects alive and disch arged 
from the intensive care unit ( ICU)at Days 14
and28
Time from randomization to first occurrence 
of respi[INVESTIGATOR_913316] (up to 
28 days after randomization) due to any 
cause
Num ber of days alive andfree of respi[INVESTIGATOR_913317] 28 days after 
randomization
Num ber of days with respi[INVESTIGATOR_913318] 28 days after randomization
Num ber of days hospi[INVESTIGATOR_913319] 28 days after randomization
Num ber of days in ICU (length of stay) from 
randomization to 90days after randomization
Num ber of days alive outside of hospi[INVESTIGATOR_913320] 28 days after 
randomization
Num ber of days alive outside of hospi[INVESTIGATOR_913320] 90 days after 
randomization
Relativ e change from baseline in 
oxygenation index (SpO2/FiO2)to Day s 3,5, 
7, and 10
Time to clinical improvement of at least 2 
points (from randomization) on a 9 -point 
category ordinal scale through Day 28 (see 
Section 8.8.1 )
Time to SpO 2> 94% on room air
Clinical Study Protocol -5.0 [COMPANY_008]
Acalabrutinib -D822FC00003
CONFIDENTIAL AND PROPRIETARY 20of 103Pharmacokinetic ( PK)Objective PK Endpoint/Variable
To assess PK of acalabrutinib and its active 
metabolite in subjects with COVID -19 when 
administered with BSCSummarized plasma concentrations of 
acalabrutinib and ACP -5862 at specified time 
points. PK parameters (eg, area under the 
concentration -time curve [AUC] and maximum 
observed concentration [C max]) estimated, as 
appropriate.
Explorato ry Objectives Exploratory Endpoints/Variables
Overall Design:
This is a mult icenter, randomized, open -label, Phase 2 study  that will evaluate acalab rutinib 
plusBSC versus BSC in subjects with COVID -19 who are hospi[INVESTIGATOR_057] .
Subjects will be randomly assigned (1:1) to receive one of the fo llowing 2 treatments:
Arm 1: Acalabrutinib 100 mg twi ce daily (bid) ×10 day s + BSC (n= 30)
Arm 2: BSC al one (n= 30)
For the purpose of this study , BSC is per di scret ion of the Invest igator and institutional 
guidelines. However, refer to Section 5.2and Section 6.5.3 for prohibited or restricted 
concomitant therapy . Subjects will be rando mized based on the fo llowing stratificat ion 
factors, which are considered prognostic factors for poor outcome:
Age ( ≥ 65 vs < 65 y ears)
Com orbidi ties (present vsabsent).  “Present” is defined as having at least 1 of the
following c omorbidities:
 Cardi ovascular di sease, as defined by [CONTACT_913364] N ew York Heart
Associ ationclass ≥2 or hy pertensi on requi ring treatm ent
 Diabetes m ellitus requi ring treatm ent
 Chronic obstructive pulmo nary disease or asthm a requi ring treatm ent
 Current active solid tumor or hematologic malignancy
CCI
Clinical Study Protocol -5.0 [COMPANY_008]
Acalabrutinib -D822FC00003
CONFIDENTIAL AND PROPRIETARY 21of 103Inclusio n/exclusio n criteria are provided in Sect ion5. Assessments are provided in 
Secti on1.1.
Study Period:
Estimated date of first subject enrolled Q2 2020.
Estimated date of last subject completed is Q3 2020.
Number of Subjects:
The total number of subjects to be randomized in this study is 60.
Treatments and Treatment Duration:
Acalabrut inib treatment should be administered within 6 hours of randomization on Day  1.
Subjects will take acalabrutinib 100 mg capsules by [CONTACT_913365] 10 day s (a m aximum  of 
20doses). Capsules will be taken with water. The capsules should be swallowed intact and 
subjects should not attempt to open capsules or diss olve them  in water.
Subjects on concomitant proton -pump inhibitors (PPIs) must take acalabrutinib wit h at least
100mL of COCA -COLA®at room  temperature. Other cola beverages (eg, Diet Coke®, 
COCA -COLA Zero Sugar) or juices are not permitted. The capsules shoul d be swall owed 
intact and subjects should not attempt to open capsules or disso lve them in COCA -COLA. 
NOTE: COCA -COLA contains glucose (5g per 100mL). Blood glucose levels of diabet ic 
subjects must be monitored as clinically indicated and blood gluc ose-lowering medicat ions 
adjusted accordingly.
Acalabrut inib can be taken wit h or without food .
Retreatment with acalabrutinib is not allowed.
BSC will be administered in both arms per Investigator’s discretion and inst itutional 
guidelines. 
Refer to Section 6.1for addi tional informat ion on treatments administered.
Internal Data Monitoring Committee:
This study  will have a n internal Data Monitoring Committee ( iDMC) , independent fro m the 
Sponsor’s study  team . Details of the roles and responsibilit ies o f the iDMC and the safet y and 
efficacy review will  be provi ded in a separate iDMC charter. The i DMC will be responsible 
forreview ing the safet y data peri odically, enable early  identificat ion of safet y signals in the 
study ,minimize risk to subjects during the study ,and make recommendat ions according to 
Clinical Study Protocol -5.[ADDRESS_1283404] of this study  in accordance 
with the iDMC charter (refer to Section 4.4for details). 
Statistical Methods :
In general, c ontinuous data will be summarized using descript ive statist ics (number of 
observat ions, m ean, standard deviat ion, median, minimum, and maximum). Frequencies and 
percentages will be used for summarizing categorical (discrete) data.
Safety will be summarized fo r the treated populat ion (Safet y popul ation) and will be based on 
the treatment they  actually  received. In this study , treatm ent is ei ther acalabrutinib + BSC or 
BSC only . If a subject receives at least [ADDRESS_1283405] of monitoring and recording AEs, SAEs ,and AEs leading to discont inuat ion of 
study  treatm ent; m easurements of protocol -specified hematol ogy, clinica l chemistry , and other 
laboratory  variables; measurement of protocol -specified vital signs; and other 
protocol -specified tests that are deemed crit ical to the safet y evaluat ion of the study  treatm ent.
For subjects randomized to Arms 1 or 2, efficacy  will be summarized for the intent -to-treat 
(ITT) popul ation, which is defined as all subjects who were randomized, to be analy zed 
according to the arm to which they are rando mly assigned, fo llowing “intent -to-treat” 
principle. Anestimate of the primary  endpo int, the proportion of subjects who are alive and 
free of respi[INVESTIGATOR_913321] D ay 28 and its 90% confidence interval (CI ;using Wald method 
with continuit y correction ) will be calculated for each treatment arm. The Cochran -Mantel -
Haenszel χ2 test s tratified by [CONTACT_654] ( ≥ 65 vs < 65 y ears) and comorbidit ies (present vs absent) 
will be used to compare the proporti on of  subjects who are alive and free of respi[INVESTIGATOR_628608] 28between the two treatment arms. An unstratified analysis will also be per formed. 
Finally , the difference in the proporti on of  subjects who are alive and free of respi[INVESTIGATOR_913322] D ay 28will also be provided wit h 90% CIs. The treatment difference will be also 
estimated using a logist ic regressio n (Ge 2011 )with indicators for treatment and the 
rando mizat ion stratificat ion factors (2 × 2) as well as baseline respi [INVESTIGATOR_33078] (withvs 
without).
Refer to Section 9for addi tional details. 
1.3 Schema
The general study  design is summarised in Figure 1.
Clinical Study Protocol -5.0 [COMPANY_008]
Acalabrutinib -D822FC00003
CONFIDENTIAL AND PROPRIETARY 23of 103Figure 1 Study Design
bid=twice per day; BSC =best supportive care (for COVID -19 sy mptoms ); SARS -CoV-2+=severe acute 
respi[INVESTIGATOR_6507] 2 positive .

Clinical Study Protocol -5.0 [COMPANY_008]
Acalabrutinib -D822FC00003
CONFIDENTIAL AND PROPRIETARY 24of 1032. INTRODUCTION
2.1 Background and Study Rationale
Coronavirus disease 2019 (COVID -19) is a new pandemic disease caused by [CONTACT_913362] [INVESTIGATOR_913323] 2 (SARS -CoV -2). In a retrospective study  of [ADDRESS_1283406] frequent ly observed co mplication, followed by 
[CONTACT_15206] [INVESTIGATOR_33078], acute respi[INVESTIGATOR_913324] e (ARDS ), heart failure, and sept ic 
shock. While sepsis might be direct ly caused by [CONTACT_7544] -CoV -[ADDRESS_1283407] COVID -19 cases (~80%) 
are mild respi[INVESTIGATOR_913314]. 5% to 15% of these respi[INVESTIGATOR_913325] 
(mostly  due to pneum onia) and can progress quickly  to severe acute l ung injury  and ARDS 
(Huang et al 2020 , Wu and McGoog an 2020 , Zhou et al 2020 ), whi ch is associ ated wi th high 
mortalit y.
Norm ally, human coronaviruses are detected and cleared by  [CONTACT_27639] , but a subset 
of patients experi ence increased severit y of symptom s (Channappanavar and Perlman 2017 , 
Zhou et al  2020 ). These sy mptom s have been associ ated wi th the l oss of control  of the virally  
induced immune response (Li et al  2020 ). In these cases, the inflammatory response is 
hypothesized to be a major pathogenic mechanism of ARDS through modulation of 
pulmonary macrophages and dendrit ic cells (Channappanavar et al 2016 , Huang et al 2005 , 
Wong et al 2004 , Yoshikawa et al 2009 )and/or neutrophils (Herol d et al  2015 ). Putative 
inflammatory  mediators include interleukin ( IL)-1β, IL-6, IL -8, IL -10, tumor necrosis factor 
alpha ( TNF α),and monocy te chem oattractant protein -1 (MCP -1)(Chen et al 2020 , Herold et 
al 2015 , Yoshikawa et al 2009 ). During the acute phase of coronavirus infect ion, T cells are 
the critical mediators of clearance of infect ion, while B cells generate a protec tive humoral 
response (Zhao et al 2009 , Zhao et al 2014 ). Generati on of  antibodies against coronaviruses is 
not always protective. In a mouse model, an ant i-spi[INVESTIGATOR_913326] s (specific to 
SARS -COV) coul d skew the inflammat ion-resolving response which lead to severe acute l ung 
injury  in mice (Liu et al  2019 ).
Bruton ’styrosine kinase (Btk) is a Tec family  nonreceptor protein kinase, expressed in 
Bcells, myelo id cells, osteoclasts, mast cells ,and pl atelets. The function of Btk in signaling 
pathways a ctivated by  [CONTACT_913363] B -cell receptor has been well established (Buggy  
and Elias 2012 ). Btk is also invo lved in the fo llowing bio logic processes: Fc gamma receptor
signaling in myelo id cells, mast cell degranulat ion, and signaling through Toll -like receptors 
(TLRs) in macrophages and neutrophils. Specifically, Btk is requi red for TLR 7/8 si gnaling, 
which recognize single strand RNA viruses such as coronaviruses, signal through Btk in 
macrophages (Page et al 2018 ).
Clinical Study Protocol -5.0 [COMPANY_008]
Acalabrutinib -D822FC00003
CONFIDENTIAL AND PROPRIETARY 25of 103Recent ly, Btk inhibit ion has shown to rescue mice fro m lethal influenza A -virus induced acute 
lung injury  by [CONTACT_913366] l ung inflammat ion and m acrophage/mo nocy te 
mediated cy tokines/chem okines (TNFα, IL -1β, IL -6, MCP -1,etc) in the lung ho mogenates. 
These results suggest that Btk inhibit ion may represent a new immuno modulatory  treatm ent 
for virally induced l ung dam age driven by [CONTACT_913367](Florence et al  2018 ). 
Addit ionally , in a murine m odel of sepsis, acalabrutinib has shown to ameliorate the cardiac 
dysfunct ion by [CONTACT_913368] -inflammatory cytokines/chemokines associated with sepsis
(O'Riordan et al 2019 ). Pati ents wi th hematol ogic malignancies treated with acalabrutinib 
(Calquence®) have shown significant reduct ion of several cy tokines/chem okines including 
pro-inflammatory markers such as: TNFα (p<0.001), IL -10 (p<0.001), MCP -1 (p<0.01), 
MIP-1β(p<0.001), MIP -1α(p<0.001), IL -16 (p<0.001), TARC (p<0.001), CXCL13 
(p<0.001), Granzyme A (p<0.001) (By[CONTACT_26753]  2016 , Covey 20 17),and IL -6 (p<0.05) (data on 
file). Several of these cy tokines/chem okines have been shown to be associated with more 
severe illness in C OVID -19 pati ents. We hypothesize that acalabrutinib treatment will inhibit 
cells that produce pro -inflammatory cytokines/chemokines, will lead to reduced inflammat ion 
of the l ungs in pat ients with COVID -19, and mit igate the pathophysio logic response that l eads 
to the m ost severe m orbidity and m ortali ty associ ated wi th viral  infect ion.Recent ly, 
encouraging results were reported in a case series of patients hospi[INVESTIGATOR_249122] -
[ADDRESS_1283408] igators at the National Institutes of Healt h 
(Roschewski 2020 ). Similarly, other BTK inhibitors have shown promise in COVID -19 
patients wi th hematol ogic malignancies (Thibaud e t al 2020 , Treon et al 2020 ).
Together , strong scientific evidence just ifies a clinical trial in this pat ient populat ion. The 
purpose of this study  is to eval uate the safet y and preliminary efficacy  of adding acalabrut inib 
to best supportive care ( BSC )for subjects hospi [INVESTIGATOR_119882] -19 symptoms.
2.2 Benefit/Risk Assessment
The l ack of  established treatments and vaccines for the novel SARS -CoV -2 virus has driven 
major m edical centers to an unprecedented overload, which has undoubtedly  contributed to 
the mortali tyobserved wi th this disease. While vaccines and ant iviral therapi[INVESTIGATOR_913327], drugs that can address the pathophy siology of the disease to decrease the morbidit y 
and mortalit y and reduce hospi[INVESTIGATOR_913328] ( ICU)use are also 
needed without delay .
Btk inhibit ion may serve as an important addit ion to the COVID -19 arm amentari um by 
[CONTACT_913369] -induced hyperimmune response, which leads to lung destruction. 
Acalabrut inib is current ly approved in the [LOCATION_002] for the treatm ent of  patients wi th 
mant le cell lympho ma or chronic lymphocyt ic leukemia/small lymphocy tic lympho ma. As of 
30Oct2019, acalabrutinib has been administered to over 3300 participants in clinical studies, 
including subjects with hematologic malignancie s, solid tumors, or rheumatoid arthritis, and 
participants who are healthy  subjects or those wi th mild to m oderate hepati c impairment. No 
Clinical Study Protocol -5.0 [COMPANY_008]
Acalabrutinib -D822FC00003
CONFIDENTIAL AND PROPRIETARY 26of 103serious adverse events ( SAEs )have been reported in the hepat ic impairment trial or in the 
healt hy vo lunteer trials. S ome subjects wi th chronic lymphocy tic leukemia have been 
receiving acalabrut inib therapy for more than 5 years. Acalabrutinib has been administered 
alone and in combinat ion with other kinase inhibit ors, anti -CD20 ant ibodies, 
chemo immunotherapy  (eg, bendam ustine/rituximab), and an ant i-programmed cell death 1 
(PD-1) receptor antibody . No dose -limit ing toxicit ies (DLTs) have been ident ified for 
acalabrutinib mo notherapy  or when administered in combination wit h the aforementioned 
agents. Current clinical safet y data supports combining acalabrutinib wit h other agents.
Refer to the acalabrut inib Invest igator ’sBrochure for the most up to date safet y and efficacy 
inform ation. Ident ified risks for acalabrut inib are summarized in Section6.6and are based on 
events observed in subjects with cancer who have been on long -term treatm ent wi th 
acalabrutinib 100 mg twice daily ( bid).
Based on the safet y profile of acalabrut inib to dat e, no overt toxicit ies have been ident ified 
that woul d precl ude acute treatment for subjects with moderate to severe COVID -19 
symptoms.
Precauti onary  safety  measures, in addit ion to regular monitoring of safet y by [CONTACT_913370] (i DMC)and the Sponsor, are included in the study  design to enable 
early  identificat ion of safet y signals in the study  and minimize the ri sk to subjects.
3. OBJECTIVES AND ENDPOINTS
Table 3 Protocol Objectives and Endpoints
Primary Objective s Primary Endpoints/Variables
To evaluate the safety of acalabrutinib in 
subjects with COVID -19 when administered 
with BSC
To evaluate the efficacy of adding 
acalabrutinib to BSC for the treatment of 
COVID -19Safety
Type, frequency, severity, and relationship to 
study treatment of any TEAEs or 
abnor malities of laboratory tests, SAEs, or 
AEs leading to discontinuation of study 
treatment.
Efficacy
Proportion of subjects alive and free of 
respi[INVESTIGATOR_226284] 28
For the purpose of this study, respi[INVESTIGATOR_7518] , is defined based on resource 
utilization of any of the following modalities:
(a)Endotracheal intubation and mechanical 
ventilation
(b)Oxygen delivered by [CONTACT_5019] -flow nasal 
cannula (heated, humidified, oxygen 
Clinical Study Protocol -5.0 [COMPANY_008]
Acalabrutinib -D822FC00003
CONFIDENTIAL AND PROPRIETARY 27of 103delivered via reinforced nasal cann ula at 
flow rates >20 L/min with fraction of 
delivered oxygen ≥0.5)
(c)Noninvasive positive pressure ventilation 
or continuous positive airway pressure 
(d)Extracorporeal membrane oxygenation 
Secondary Efficacy Objective Secondary Efficacy Endpoints/Variables:
To evaluate the efficacy of adding acalabrutinib 
to BSC for the treatment of COVID -19Proportion of subjects alive and free of 
respi[INVESTIGATOR_1399] (as defined above) at 
Day 14
Percent c hange from baseline in CRP (time 
frame: baseline, Days 3, 5, 7, 10 , 14, 28 )
Change from baseline in ferritin (time frame: 
baseline, Days 3, 5, 7, 10 , 14, 28 )
Change from baseline in absolute 
lymphocyte counts (time frame: baseline, 
Days 3, 5, 7, 10 , 14, 28 )
All-cause mortality at Day 90
Proportion of subjects alive and dis charged 
from the ICU at Days 14 and28
Time from randomization to first occurrence 
of respi[INVESTIGATOR_913316] (up to 
28 days after randomization) due to any 
cause
Num ber of days alive and free of respi[INVESTIGATOR_913317] 28 days after 
randomization
Num ber of days with respi[INVESTIGATOR_913318] 28 days after randomization
Num ber of days hospi[INVESTIGATOR_913319] 28 days after randomization
Num ber of days in ICU (length of stay ) from 
randomization to 90days after randomization
Num ber of days alive outside of hospi[INVESTIGATOR_913320] 28 days after 
randomization
Num ber of days alive outside of hospi[INVESTIGATOR_913320] 90 days after 
randomization
Relative change from b aseline in 
oxygenation index ( SpO2/FiO2) to Day s3, 5, 
7, and 10
Time to clinical improvement of at least 2 
points (from randomization) on a 9 -point 
Clinical Study Protocol -5.0 [COMPANY_008]
Acalabrutinib -D822FC00003
CONFIDENTIAL AND PROPRIETARY 28of 103category ordinal scale through Day 28 ( see
Section 8.8.1 )
Time to SpO 2> 94% on room air
PKObjective PK Endpoints/Variables
To assess PK of acalabrutinib and its active 
metabolite in subjects with COVID -19 when 
administered with BSCSummarized plasm a concentrations of 
acalabrutinib and ACP -5862 at specified time 
points. PK parameters (eg, AUC and C max) 
estimated, as appropriate.
Exploratory Objectives Exploratory Endpoints/Variables
AE = adverse event; AUC = area under the concentration -time curve; BSC = best supportive care; 
 CL/F = apparent clearance; Cmax= maximum observed concentration; 
COVID -19 = coronavirus disease 2019; CRP = C-reactive protein; FiO 2=fraction of inspi[INVESTIGATOR_1401] ; 
ICU = intensive care unit;  
 PK = pharmacokinetics; SAE = serious adverse event; SARS -CoV -2 = severe acute respi[INVESTIGATOR_913329] 2; SpO 2= oxygen saturation; t1/2= half -life; TEAE = treatment -emergent adverse 
event; tmax= time to maximum observed concentration;  Vd ss/F=apparent 
volume of distribution at steady -state .
4. STUDY DESIGN
4.1 Overall Design
This is a mult icenter, randomized, open -label, Phase 2 study  that will evaluate acalabrutinib 
plus BSC versus BSC in subjects withCOVID -19 who are hospi[INVESTIGATOR_057] .
Subjects will be rando mly assigned (1:1) to receive one of the fo llowing 2 treatm ents:
Arm 1:  Acalabrut inib 100 mg bid ×10 day s + BSC (n= 30)
Arm 2:  BSC al one (n= 30)
For the purpose of this study , BSC is per di scret ion of the Invest igator and institutional 
guidelines. However, refer to Section 5.2and Section 6.5.3 for prohibited or restricted 
concomitant therapy . Subjects will be rando mized based on the fo llowing stratificat ion 
factors, which are considered prognostic factors for poor outcome:
CCI
CCI
CCI
CCI
Clinical Study Protocol -5.0 [COMPANY_008]
Acalabrutinib -D822FC00003
CONFIDENTIAL AND PROPRIETARY 29of 103Age ( ≥ 65 vs < 65 y ears)
Com orbidi ties (present vsabsent). “Present” is defined as having at least 1 of the 
following c omorbidities: 
Cardi ovascular di sease, as defined by [CONTACT_913371] (NYHA )class ≥2 or hy pertensi on requi ring tr eatm ent
Diabetes m ellitus requi ring treatm ent
Chronic obstructive pulmo nary disease or asthm a requi ring treatm ent
Current active solid tumor or hematologic malignancy
Inclusio n/exclusio n criteria are provided in Section5. Assessments are provided in 
Secti on1.1.
4.2 Scientific Rationale for Study Design
The immune system is required to clear viral infectio ns and generate protective immunit y 
from viral pathogens like SARS -CoV-2. There is significant evid ence that in pati ents wi th 
severe respi[INVESTIGATOR_913330], the immune system and inflammat ion contribute to the severit y 
of the di sease. Macrophages and neutrophils are key  to producing cy tokines driving thi s 
inflammat ion. The hypothesis being evaluated in th is trial is whether Btk inhibit ionofthe 
viral-induced macrophage and neutrophil immune response can decrease inflammat ion and 
reduce respi [INVESTIGATOR_913331] . Given the various covariates that contribute to these 
outcom es (eg, l ack of consensus on st andard of care, actively changing local treatment 
practi ces, and pati ents’ com orbid condi tions), a singl e-arm study  will likely  not be informative 
as data from historical controls are changing almost daily. Hence, this will be a rando mized 
study . Subjects who are hospi [INVESTIGATOR_191544] -19 disease and m eet the eligibilit y criteria 
will be rando mized 1:1 to receive acalabrutinib plus BSC (n= 30) versus BSC (n= 30).
Stratificat ion by [CONTACT_913372].
4.3 Justification for Dose
Acalabrut inib 100 mg bid hasbeen evaluated in various indications (ie, B -cell malignancies 
and so lid tumours) alone and in co mbinat ion with anti-CD20 ant ibodies, chemotherapy, a 
phosphatidylino sitol-3-kinas e (PI3K) inhibitor, and an ant i-PD-[ADDRESS_1283409] 
been ident ified for acal abrut inib alo ne or when given in co mbinat ion with these agents. For all 
ofthese indications, acalabrut inib was administered daily unt il disease progression; so me 
subjects have been receiving acalabrut inib for > 5 years. The lo ng-term safet y experi ence of 
chronic administration of acalabrut inib 100 mg bid monotherapy  and in combinat ion with 
other agents, supports the proposed dosage of acalabrut inib is 100 mg bid for acute t reatm ent. 
In addit ion, correl ative studies —in subjects wi th chronic lymphocy tic leukemia treated with 
acalabrutinib 200 mg once daily ( qd)or 100 mg bid —show bid dosing maintained higher Btk 
Clinical Study Protocol -5.[ADDRESS_1283410] inhibit ion compared wi th qd dosing 
(Sun et al  2020 ). Activat ion of NF- kappaB occurs in the lungs of pat ients with ARDS and 
may contribute to the increased e xpressio n of proinflammatory  mediators (Moine et al 2000 ). 
Therefore, [ADDRESS_1283411] 
30subjects (approximately 15 subjects per arm) are randomized. 
In addit ion, if at any  time during the conduct of the study  either of the cri teria bel ow are met, 
enrollment of addit ional subjects will be paused such that the iDMC would convene and 
conduct a full safet y review.
Any death due to acalabrutinib (per Invest igator )
≥20% treatm ent di scont inuat ion rate due to toxicit y attributed to acalabrutinib (per
Invest igator) , when [ADDRESS_1283412] been treated
Any Grade 4 hemorrhage due to acalabrutinib (per Invest igator)
During the safet y review, the i DMC wi th com pare the known adverse event ( AE)profile 
associ ated wi th acalabrutinib wit h comprehensive safet y data fro m the current study . The 
iDMC will determine if an unacceptable increase in Grade [ADDRESS_1283413] expec ted visi t/contact [CONTACT_17008] l ast subject undergoing the 
study .
A subject i s considered to have co mpleted the study when he/she has co mpleted his/her last 
scheduled procedure shown in the Schedule of Activit ies (SoA; Section1.1). All rando mized 
subjects will be fo llowed for survival through 90 (± 7) days after randomizat ion.
Clinical Study Protocol -5.[ADDRESS_1283414] a safet y follow up assessment 
28(± 3) days after the last dose of acalabrutinib (Arm  1), or 38 (± 3 day s) after randomizat ion 
for those subj ects randomized to the BSC arm (Arm 2), as outlined in Section1.1.
The study  may be stopped if, in the judgment of the Sponsor , study  subjects are placed at 
undue risk because o f clinically significant findings.
See Appendix A6for guidelines for the dissemination of study  resul ts.
5. STUDY POPULATION
Prospective approval o f protocol  devia tions to recrui tment and enro llment criteria, also known 
as protocol waivers or exemptions, is not permitted.
Each subject should meet all the inclusio n criteria and none of the exclusio n criteria for thi s 
study  to be assigned to a study  intervent ion. Unde r no ci rcumstances can there be except ions 
to this rul e. Subjects who do not meet the entry  requi rements are screen failures, refer to 
Secti on5.3.
5.[ADDRESS_1283415] a legal representative provide consent and authoriz ation to use 
protected healt h informat ion (in accordance wit h national and local pat ient privacy 
regul ations).
2. Men and wo men ≥18 years of age at the time o f signing the Inform ed Consent Form 
(ICF).
3. SARS -CoV -2 confirmed per World Healt h Organization criteria (including posi tive 
nucleic acid test of any  specimen [eg, respi [INVESTIGATOR_696] , blood, uri ne, stool , or other bodily  
fluid])within 7days o f rando mizat ion.
4. COVID -19pneumonia (docum ented radi ographically ) requi ring hospi [INVESTIGATOR_913332] <94% on room  air or requi res suppl emental oxygen .
5. Able to swallow pi[INVESTIGATOR_3353].
6. Willing to follow contraception guidelines (refer to Appendix F).
5.2 Exclusion Criteria 
Subjects are excluded fro m the study  if anyof the criteria below apply .
Clinical Study Protocol -5.0 [COMPANY_008]
Acalabrutinib -D822FC00003
CONFIDENTIAL AND PROPRIETARY 32of 103COVID -19 Related Medical Conditions
1. Respi[INVESTIGATOR_913333] (seeSecti on 3for definit ion of respi[INVESTIGATOR_36639] ) due to COVID -[ADDRESS_1283416] igator’ s judgment, precludes the subject’ s safe parti cipat ion in an d com pletion of  
the stud y.
4. Suspected uncontrolled active bacterial, fungal, viral, or other infect ion (besides 
infect ion with SARS -CoV -2).
5. In the opi[INVESTIGATOR_1649] o f the Invest igator , progression to death is imminent and inevitable wit hin 
the next [ADDRESS_1283417], the fo llowing condi tions: 
multiorgan failure, poorly  controlled neoplasms; endstage cardiac disease; cardiac arrest 
requi ring cardiopulmo nary resusci tation or wi th pulseless electrical act ivity or asy stole 
within past 30 day s; endstage l ung disease; endstage liver disease; or human 
immunodeficiency  virus (HIV)/acqui red immun odeficiency syndro mewith known 
endstage process .
7. Pregnant or breast feeding .
8. Alanine aminotransferase (ALT) , aspartate aminotransferase (AST) and/or bilirubin 
≥3×upper limit of normal (ULN) and/or severe hepatic impairment (Child -Pugh 
classC; see Appendix G) detected during the screening period (per l ocal laboratory ).
Except ion:AST and/or ALT can be up to 5 ×ULN if considered due to underlying 
COVID -19 disease, but cannot be associated with concurrent elevated bilirubin (up to 
2×ULN) .
9. Absolute neutrophil count (ANC) < 500/µL at screening (per local lab oratory ).
10. Platelet coun t < 50,000/µL at screening (per local lab oratory ).
11. Estimated creatinine clearance of <30 mL/min calculated using the Cockcroft -Gaul t 
formula [(140age) × m ass (kg)/(72 × creatinine mg/dL) mult iply by 0.85 if female] .
12. Uncontrolled or untreated symptomat ic arrhyt hmias, myo cardi al infarct ion within the 
last 6 weeks, or congestive heart failure (NYHA Grade 3 or 4). 
Except ion: Subjects wi th controlled, asymptomatic atrial fibrillat ion during screening are 
allowed to enroll on study .
13. History of chronic hypercarbia, respi[INVESTIGATOR_913334] 6 months ,or use of home 
oxygen in the setting of severe chronic respi[INVESTIGATOR_23715] .
Clinical Study Protocol -5.0 [COMPANY_008]
Acalabrutinib -D822FC00003
CONFIDENTIAL AND PROPRIETARY 33of [ZIP_CODE]. Quadri plegia .
15. History  of primary  immunodeficiency, tuberculosis, progressive mult ifocal 
leukoencephalopathy  (PML), aspergillus or other invasive mold/fungal infect ion,or 
received organ or b one m arrow transplantation within [ADDRESS_1283418] ion.
a)Subjects who are hepatit is B core antibody (anti -HBc) posi tive and who are 
hepat itisB surface antigen (HBsAg) negat ive will need to have a negat ive or 
undetectable hepat itis B viral load by [CONTACT_602685] (PCR) 
resul t before randomizati on. Those who are HBsAg posit ive or have detectable 
hepat itis B viral load by [CONTACT_913373].
b)Subjects who are hepatit is Cvirus (HCV) ant ibody posit ive will need to have a 
negat ive PCR result before randomization. Those who are hepatit is C PCR posit ive 
will be excluded.
17. Known active HIV with detectabl e viral lo ad orCD4 counts < 500cells/mm3.
Prior/ Concomitant Therapy
18. Treatment with a strong cytochrom e P450 ( CYP )3A inhibitor (within [ADDRESS_1283419] 
dose of study  drug )or inducer (within [ADDRESS_1283420] dose of study  drug) .
19. Subjects are excluded who have already received prior immuno modulatory / 
immunosuppressive treatment intended as specific treatment for COVID -19 (after 
rando mizat ion these agents may be permitted –see Section 6.5.2 ). Note: Steroids are 
permitted prior to randomizat ion and on study ..
20. Active participation in other drug clinical trials or received t reatm ent wi th an 
investigat ional drug wi thin 5 half -lives or 30 day s (whi chever is l onger) of 
rando mizat ion/enrol lment . 
Except ion:Subjects may receive COVID -19-specific antiviral drugs (eg,remdesivir, 
hydroxy chloroquine) .
21. Requi res or is receiving specific anticoagulation wit h warfarin or equivalent vitamin K 
antagonists (eg, phenprocoumon) within 7 days prior to randomization .Other 
anticoagulants are permitted.
22. Subjects on dual antiplatelet andtherapeuti c anticoagul ant therapy (eg, aspi[INVESTIGATOR_913335] ).
23. History  of hypersensi tivity (ie, allergic response) to active or inact ive excipi[INVESTIGATOR_913336] .
24. Known cy toreductive chem otherapy  treatm ent wi thin14 days of randomizat ion.
25. Major surgery  (as defined by [CONTACT_11856] ) within 4 weeks prior to randomizat ion or 
still recovering fro m prior surgery .
Clinical Study Protocol -5.0 [COMPANY_008]
Acalabrutinib -D822FC00003
CONFIDENTIAL AND PROPRIETARY 34of 1035.3 Screen Failures
Screen failures are defined as subjects who consent to participate in the clinical study  but are 
not subsequently rando mized . A minimal set of screen failure informat ion is required to 
ensure transparent reporting of screen failure subjects to meet the Consolidated Standards of 
Reporting Trials (CONSORT) publishing requirements and to respond to queries fro m 
regul atory authori ties. Minimal informat ion includes demography, screen failure details, 
eligibilit y criteria, and any SAE unrelated to the disease under invest igation.
Individuals who do not meet the criteria for participation in this study  (screen failure) m aybe
rescreened. Rescreened subjects shoul d be assigned the same subject number as for the init ial 
screening.
6. STUDY TREATMENTS
Study  treatm ent is defined as any invest igational product(s) (including marketed product 
comparator and pl acebo) or m edical device(s) intended to be administered to a study  subject 
according to the study  protocol . Study  treatm ent in this study  refers to acal abrut inib.
6.1 Treatments Administered
6.1.1 Dosing and Duration of Treatment
Acalabrut inib treatment should be administered within 6 hours of randomization on Day  1. 
Subjects will take acalabrutinib 100 mg capsules by [CONTACT_913374] 10 day s (a m aximum  of 
20doses) . Capsul es will be taken with water. The capsules should be swallowed intact and 
subjects should not attempt to open capsules or d issolve them in water. For subjects requiring 
a proton -pump inhibitor (PPI), acalabrut inib must be administered as described in 
Secti on6.1.3.1 .
Acalabrut inib can be taken wi th or wi thout food. 
Retreatment with acalabrutinib is not allowed.
BSC will be administered in both arms per Investigator’s discretion and inst itutional 
guidelines.
6.1.2 Missed Dosing Windows and Doses
The bid d oses shoul d be scheduled approximately  12hours apart. It is reco mmended that 
acalabrutinib be taken as close to the scheduled time as possible (wit hin ±1 hour). However, if 
the scheduled t imeis missed, it can be taken up to 3 hours after the scheduled ti me, wi th a 
return to the normal schedule upon the fo llowing dose for 10 day s(a maximum  of 20 doses) .
Clinical Study Protocol -5.[ADDRESS_1283421] be skipped on that day . Study  drug m ay 
be held for a maximum o f 3consecutive days (6 consecut ive dos es) fro m expected dose due to 
toxicity. If a dose is missed due to an adverse event (AE) or for any  other reason, missed 
doses should be completed so the subject receives a maximum o f 20 doses of study  drug, even 
if this is bey ond the 10 -day dosi ng period.
6.1.3 Special Considerations
[IP_ADDRESS] Drug -drug Interactions
Drug -drug i nteracti ons m ay occur wi th som e of the drugs being used as BSC (eg, drugs that 
are moderate inhibitor of CYP3A , gastri c acid reducing agents ), and dosing of acalabrut inib 
may need to be adjusted. Please refer to Secti on6.5.[ADDRESS_1283422] take acalabrut inib wit h at least100mL of COCA -COLA®
at room  temperature. Other cola beverages (eg, Diet Coke®, COCA -COLA Zero Sugar) or 
juices are not permitted. The capsules should be swallowed intact and subjects should not 
attem pt to open capsules or disso lve them in COCA -COLA. NOTE: COCA -COLA contains 
glucose (5g per 100mL). Blood glucose levels of diabet ic subjects must be monitored as 
clinically indicated and blood glucose -lowering medi cations adj usted accordingly.
Administrati on of  acalabrutinib wit h COCA -COLA mit igates the effe ct of PPIs. Several  
acidic beverages wi th pH similar to COCA -COLA were assessed (eg, orange drink, lemo nade, 
COCA -COLA Zero Sugar, cranberry  juice, and grapefruit juice) but not found to be optimal. 
In healthy subjects, pharmacokinet ic (PK) exposure fo llowing 100 -mg acalabrut inib 
suspension in COCA -COLA (nasogastri c delivery) is similar in the presence or absence of 
PPIs, and com parable to that of the 100 -mg acalabrutinib capsule. In addit ion, based on a 
verified physio logically -based biopharmaceut ics model (Pepin et al 2019 ), acal abrutinib 
exposure is predicted to be similar between the administration of 100 -mg acalabrutinib 
capsule with 100mL COCA -COLA in the pres ence of PPIs and the 100 -mg acalabrutinib 
capsule taken with water. Overall, these data support the use of acalabrutinib in subjects who 
need to take PPIs for the management of various acid -related disorders.
[IP_ADDRESS] Subjects With Respi[INVESTIGATOR_913337] S till Swallow Pi[INVESTIGATOR_913338] [ADDRESS_1283423] igato r’s clinical judgment.
[IP_ADDRESS] Subjects No Longer Able to Swallow Pi[INVESTIGATOR_913339].
Clinical Study Protocol -5.[ADDRESS_1283424] should not retake acalabrut inib unt il 
the next scheduled dose.
[IP_ADDRESS] Discharged From  Hospi[INVESTIGATOR_913340] 10 days (20 doses) 
of acalabrutinib therapy  will be requi red to com plete the rem aining dosing at home. They  
shoul d adhere to thei r established dosing schedule and treatment guidelines, including in cases 
where subjects remain on PPIs . These subjects must complete a drug dosing diary  to be faxed 
or mailed back to the study  site.
6.2 Acalabrutinib Preparation/Handling/Storage/Accountability
Acalabrut inib shoul d be stored according to the instructions on the label affixed to the 
package of the drug product.
If a drug shipment arrives damaged or if there are any other drug complaints, a Product 
Com plaint Form  shoul d be co mpleted and emailed to the Sponsor or the Sponsor’s 
representative. Refer to the pharmacy manual and the Invest igator ’sBrochure for addit ional 
inform ation regarding the drug product to be used in this study .
The Investigator or designee (eg, pharmacist) must confirm appropriate temperature 
condi tions have been maintained during transit for all study  treatm ent received and any 
discrepancies are reported and resolved before use of the study  treatm ent.
Only subjects enro lled in the study  may receive study  treatm ent and only authorized site staff 
may supply  or administer study  treatm ent. All  study  treatm ents m ust be stored in a secure, 
environmenta lly controlled, and monitored (manual or automated) area in accordance with the 
labeled storage condit ions with access limited to th e Invest igator and authorized site staff.
The Investigator, inst itution, or the head of the medical inst itution (where appli cable) i s 
responsible for study  treatm ent accountabilit y, reconciliat ion, and record maintenance (ie, 
recei pt, reconciliat ion, and final disposit ion records).
Further gui dance and information for the final disposit ion of unused study  treatm ent are 
provi dedin the Clinical Study  Agreement.
6.3 Measures to Minimise Bias: Randomisation and Blinding
Given the urgent nature of th eCOVID -[ADDRESS_1283425] Enrollment and Randomization
All eligible subjects will be centrally randomized using an interactive response technology  
(IRT) that will assign the subjects to either acalabrutinib plus BSC versus BSC , stratified by  
[CONTACT_913375] 4.1. Before the study is init iated, l og-in 
inform ation and di rectionsfor the IRT will be provided to each site . 
Invest igators should keep a record (ie, the subject screening log) of subjects who en tered 
screening. 
At screening, the Invest igator s or suitably trained delegate will:
Obtain informed consent before any study  specific procedures are performed.
Obtain a unique 7 -digit enrollment number (E -code), through the IRTthe following 
format (ECCNN XXX: CC being the country  code, NN being the center number, and 
XXX being the subject enrollment code at the center). This number is the subject ’s unique 
ident ifier and is used to ident ify the subject on the electroni c case report forms ( eCRFs ).
Determine subject eligibilit y (see Secti on 5.1and Secti on 5.2).
At randomizat ion, once the subject is confirmed to be eligible, the Invest igator or suitably 
trained delegate will:
Log the E -code and stratificat ion factors ( age [≥ 65 vs < 65 y ears]and comorbidi ties 
[present vs absent ])in the IRT system and the system will sequentially rando mize the 
eligible subject to 1 of the 2 treatment arms. 
If the subject is ineligible and not randomized, the IRT should be contact[CONTACT_913376] . 
Subjects will begin treatment on Day  1. Treatm ent shoul d start no more than [ADDRESS_1283426] withdraws fro m participat ion in the study , then his /her enro llment/randomization 
code cannot be reused. A withdrawn subject will not be replaced.
[IP_ADDRESS] Procedures for Handling Incorrectly Enrolled or Randomized Subjects
Subjects who fail to meet the eligibilit y criteria shoul d not, under any  circumstances, be 
enrolled or receive study  medicat ion. There can be no exceptions to this rule. Subjects who are 
enrolled, but subsequent ly found not to m eet all the eligibilit y criteria must not be randomized 
or init iated on treatment and must be withdrawn from the study .
Where a subjec t does not m eet all  the eligibilit y criteri a but i s rando mized in error, or 
incorrectly  started on treatm ent, the Invest igator should inform the study physician 
immediately , and a discussi on shoul d occur between the study physician and the Investi gator
Clinical Study Protocol -5.[ADDRESS_1283427] ensure all decisio ns are appropriately documented and tha t the potential benefit:risk 
profile remains posit ive for the subject .
[IP_ADDRESS] Methods for Assigning Treatment Groups
The actual  treatm ent assigned to subjects will be determined by [CONTACT_913377]. A stratified permuted block randomization scheme will  be used, wi th the 
stratificat ion factors defined in Section 4.1. The rando mizat ion scheme will be produced by  a 
computer software program that incorporates a standard procedure for generating 
rando mizat ion numbers. 
Randomization codes will be assigned strict ly sequent ially, within each stratum, as subjects 
beco me eligi ble for randomizat ion. 
[IP_ADDRESS] Methods for Ensuring Blinding
This is an open -label study  for the personnel at study  sites. Specific treatment to be taken by  a 
subject will be assigned using an IRT. The site will contact [CONTACT_913378] . The si te will record the treatment assignment on the 
applicable case report form, if required. To maintain the integrity  of the study , the Sponsor ’s 
personnel direct ly involved in the study  conduct will, under no ci rcums tances , view data 
aggregated by  [CONTACT_913379] .
6.[ADDRESS_1283428] igator(s) is responsible for ensuring that all 
unused investiga tional product is returned to the site by  [CONTACT_423](s) .
6.[ADDRESS_1283429] ion 6.5.3. Given the rap id emergence of new data related to COVID -19, BSC could 
Clinical Study Protocol -5.0 [COMPANY_008]
Acalabrutinib -D822FC00003
CONFIDENTIAL AND PROPRIETARY 39of 103change during the duration of the study . The use of therapi[INVESTIGATOR_913341], therapeutic 
plasma, corti costeroi ds, or other immuno modulatory  agents (eg, tocilizumab) is permitted if 
recommended by  [CONTACT_913380]. The 
concomitant administration o f immunosuppressive agents with acalabrutinib may require 
additional safety  monitoring as determined by [CONTACT_68071]. Investigators should 
maintain prohibit ions of certain concurrent medications for other reasons as listed in 
Secti on6.5.[ADDRESS_1283430] itutional guidelines ,are prohibited for all randomized subjects in 
the study  through Day  28. Subjects who are taking immuno modulatory  drugs for other 
medical condit ions (eg, tocilizumab for rheumatoid arthrit is) may cont inue with treatment 
upon discussio n with the Medical Monitor . 
Medications Prohibited for All Subjects in Both Treatment Arms Through Day 10
Strong CYP3A inhibitors or inducers: Drug -drug interactions may occur with so me of the 
drugs being used as BSC (eg, drugs that are strong inducers or strong inhibitors of CYP3A). 
The concomitant use of strong inhibitors of CYP3A (see Appendix E) shoul d be avoi dedby 
[CONTACT_913381] . If a subject requi res a strong CYP3A inhibitor while on treatment 
with acalabrutinib, discont inue acalabrutinib treatment. Conversely, conco mitant 
admini strati on of  a strong inducer of CYP3A has the potential to decrease exposure of 
acalabrutinib and could reduce efficacy. Therefore, the concomitant use of strong CYP3A 
inducers should be avoided by [CONTACT_913382] . If a subject requi res a strong CYP3A 
inducer while on treatment with acalabrutinib, discontinue acalabrut inib. For addit ional 
inform ation on drugs with potential drug -drug interacti ons, refer to Secti on 6.5.4 .
Certain a nticoagulants: Warfarin or equivalent vitamin K antagonists (eg, phenprocoumon) 
are prohibited for all subjects in the study . Subjects who require prophylaxis or t herapeutic 
anticoagulationfor thrombosis (deep vein thro mbosis or pulmo nary embo lism) will be 
allowed to receive therapeut ic anticoagul ation with a non -vitamin K inhibitor class of 
anticoagulants (eg, heparin or low -molecular -weight heparin) .
Refer to Section 5.2foraddit ional restrict ions on concomitant therapy . 
Clinical Study Protocol -5.[ADDRESS_1283431] ion and abilit y to achieve 
pharmacodynamic (PD) Btk receptor occupancy steady -state in target B -cell and m onocy tic 
popul ations. Therefore, t he Sponsor recommends that all eligible subjects with COVID -19 
begin dosing with acalabrut inib 100 mg bid. The durati on of  acalabrutinib therapy  will be 
limited to 10 days (a maximum of 20 doses) . Table 4provides moderate CYP3A inhibitors
and acid reducing agent guidance for subjects with COVID -19. Refer to Appendix Efor a list 
of commo n CYP3A inhibitors/inducers and gastric acid reducing medicines.
Table 4 Acalabrutinib Use with Moderate CYP3A Inhibitors and Gastric Acid 
Reducing A gents
Co-administered 
Medicines Recommended Acalabrutinib Use
CYP3A 
InhibitorModerate CYP3A 
inhibitor Monitor subjects closely for adverse reactions if taking 
moderate CYP3A inhibitors. For subjects who 
experience an intolerable adverse event (ie, Grade 3 -4) 
attributed to acalabrutinib therapy, reduce the dose to 
100mg once daily.
Gastric Acid 
Reducing 
MedicinesProton -pump inhibitors 
(PPIs)Avoid concomitant use. If PPI [INVESTIGATOR_913342], dose modification of acalabrutinib is not 
necessary; however, acalabrutinib must be 
administered with at least 100 mL of COCA -COLA to 
improve acalabrutinib absorption (refer to 
Section [IP_ADDRESS] ). Other cola beverages are not 
permitted.
H2-receptor antagonists Take acalabrutinib [ADDRESS_1283432] 2 hours.
[IP_ADDRESS] Active Substances That May Increase Acalabrutinib Plasma Concentrations
CYP3A  Inhibitors
Co-administration with a strong CYP3A inhibitor (200 mg itraconazo le qdfor 5 day s) 
increased acalabrutinib maximum observed concentrati on (C max)and area under the 
concentration -time curve ( AUC )by 3.7 -and 5.1 -fold in healt hy subjects (N=17), respectively.
Clinical Study Protocol -5.[ADDRESS_1283433] ivity. In subjects 
requi ring strong CYP3A inhibitors (eg, ketoco nazol e, conivaptan, clarithromycin, indinavir, 
itraconazo le, ritonavir, telaprevir, posaconazole, voriconazo le),discont inue acalabrut inib
treatm ent. 
[IP_ADDRESS] Active Substances That May Decrease Acalabrutinib Plasma Concentrations
CYP3A  Inducers 
Co-administration of a strong CYP3A inducer (600 mg rifampin qdfor 9 days) decreased 
acalabrutinib Cmax and AUC by 68% and 77% in healthy subjects (N=24), respectively.
Consider alternat ive therapi[INVESTIGATOR_913343]3A act ivity (eg, pheny toin, rifam pin, 
carbamazepi[INVESTIGATOR_050]). Avo id St. John’s wort which may unpredictably decrease acalabrutinib 
plasma concentrations. If these inducers cannot be avo ided, discont inue acalabrutinib 
treatm ent.
Gastric Acid Reducing Medications
Acalabrut inib solubility decreases with increasing pH. Co -administration of acalabrut inib wit h 
an antacid (1 g calcium carbonate) decreased acalabrutinib AUC by 53% in healt hy subjects. 
Co-administration with a PPI(40mg omeprazo le for 5 day s), decreased acalabrut inib AUC by 
43%.
If treat ment with an aci d reducing agent i s requi red, consider using an antacid (eg, calcium 
carbonate), or an H2 -receptor antagonist (eg, famotidine). For use with antacids, separate 
dosing by  [CONTACT_2669] [ADDRESS_1283434] ion with acalabrut inib. In subjects requiring treatm ent wi th PPIs (eg, omeprazo le, 
esomeprazo le, lansoprazole, dexlansoprazole, rabeprazole, or pantoprazole )during the study , 
acalabrutinib must be administered with at least 100 mL COCA -COLA at room  temperature 
to improve acalabrut inib absorption (see Section [IP_ADDRESS] ). Other cola beverages are not 
permitted . 
Dose m odificat ion of acalabrutinib is not necessary when co -administered with gastric acid 
reducing medicat ions.
6.[ADDRESS_1283435] from pat ients with hematol ogic m alignancies, the populat ion 
for which acalabrut inib is indicated, and the duration of acalabrut inib tr eatm ent for COVID -19 
is much shorter than for the indicated populat ion with hematol ogic malignancies. Therefore, 
Clinical Study Protocol -5.0 [COMPANY_008]
Acalabrutinib -D822FC00003
CONFIDENTIAL AND PROPRIETARY 42of 103the safet y profile of acalabrutinib in the COVID -19 populati on may  differ f rom that 
established in the cancer population.
The experience with c hronic administration of acalabrut inib in hematol ogic cancer studi esis 
described below . Table 5summarizes the risks associated with acalabrutinib (any grade, 
≥Grade [ADDRESS_1283436] onset) based on 1040 subjects with hematologic 
malignancies who received acalabrut inib monotherapy  (data on file).
For m ore detailed informat ion on treatm ent-emergent adverse events (TE AEs), refer to the 
acalabrutinib Invest igator ’sBrochure. Full details regarding the clinical safet y of acalabrutinib 
are presented in Sect ions 5 and 6 of the acalabrutinib Investigator’s Brochure.
Table 5 Risks Associated with Acalabrutinib Monotherapy in Subjects With 
Hemato logic Malignancies (N = 1040)
Event categoryNumber (%) of subjects Median ( min, max ), months
Any grade ≥Grade [ADDRESS_1283437] onset
Hemorrhage 482 (46.3) 28 (2.7) 1.2 (0, 53)
Major hemorrhage 37 (3.6) 28 (2.7) 9.8 (0, 44)
Infections 694 (66.7) 183 (17.6) 3.2 (0, 45)
Anemia 144 (13.8) 81 (7.8) 0.7 (0, 41)
Neutropenia 163 (15.7) 148 (14.2) 3.1 (0, 44)
Thrombocytopenia 93 (8.9) 50 (4.8) 1.7 (0, 39)
Second primary malignancy 127 (12.2) 43 (4.1) 9.5 (0, 50)
Atrial fibrillation 46 (4.4) 13 (1.3) 17.4 (0, 43)
max = maximum; min = minimum.
6.6.[ADDRESS_1283438] been reported in subjects treated with 
acalabrutinib (eg, asperg illosis). Subjects should be monitored for signs and symptoms of 
infect ion and treated as medically appropriate. Please refer to Secti on6.7for study  drug 
modificat ion guidance.
Clinical Study Protocol -5.0 [COMPANY_008]
Acalabrutinib -D822FC00003
CONFIDENTIAL AND PROPRIETARY 43of 1036.6.3 Hepatitis B Reactivation
Across the acalabrutinib clinical development program, 9 subjects had hepat itis B virus 
(HBV) reactivation. Seven o f the 9 subjects develo ped HBV reactivat ion after receiving 
acalabrutinib, and 2 subjects had HBV reac tivati on pri or to receiving (crossover) 
acalabrutinib. One subject experienced a serious Grade [ADDRESS_1283439] wi th a rising vi ral load (above l ower limit of detection) 
shoul d discont inue study  treatment and have antiviral therapy  instituted and a consultation 
with a physician wit h expertise in managing hepat itis B. Insufficient data exist regarding the 
safet y of resuming acalabrut inib in subjects who develop HBV react ivation.
6.6.[ADDRESS_1283440] s had events of PML (both 
serious) af ter receiving acalabrutinib . Signs and symptom s of PML m ay include cognit ive and 
behavioral changes, language disturbances, visual disturbances, sensory  deficits, weakness, 
and coordi nation and gai t difficul ties. Please refer to Section 6.7for study  drug m odificat ion 
guidance .
6.6.[ADDRESS_1283441] 
frequent second primary  malignancy was skin cancer (squamous basal cell carcino ma of the 
skin). Subjects should be monitored for signs and symptoms of malignancy. Subjects who 
develop a malignancy  should be managed according to inst itutional guidelines wi th diagnosti c 
evaluat ions or as clinically indicated, and it may be necessary  for subjects to perm anent ly 
discontinue study  treatm ent. Continuat ion of acalabrutinib treatment should be discussed wit h 
the Medi cal Monitor.
6.6.7 Atrial Fibrill ation 
Moni tor for sym ptoms of atri al fibrillat ion and atrial flutter (eg, palpi[INVESTIGATOR_53895], dizziness, 
syncope, chest pain, dyspnea), and obtain an electrocardiogram ( ECG )as clinically indicated. 
Subjects with atrial fibrillat ion shoul d be m anaged per instit utional guidelines wit h supportive 
care and diagnost ic evaluat ions or as clinically indicated. Please refer to Section 6.7for study  
drug m odificat ion gui dance.
Clinical Study Protocol -5.[ADDRESS_1283442] igator ’sBrochure for 
assessment of expectedness of serious a dverse reacti ons.
6.[ADDRESS_1283443] experiences a Grade 1 or 
Grade 2 AE . Acalabrut inib therapy should be modified or discont inued , however, for the 
following AEs:
Event Acalabrutinib Dose Modification /Discontinuation
Hematological
Grade 4 neutrophil count decrease 
(ANC <500/μL)• Hold acalabrutinib ,and consider introduc ing
growth factors (eg, G-CSF) and continue to 
monitor ANC
• If neutropenia has improved to Grade 1 or 
baseline within 3 days of event onset , restart 
acalabrutinib
• If neutropenia has notimpro ved to Grade 1 or 
baseline within 3 days of event onset, discontinue 
acalabrutinib
Any grade febrile neutropenia lasting more 
than 2 days• Discontinue acalabrutinib
• Consider i ntroduc inggrowth factors (eg ,G-CSF), 
evaluate subject for infection, and begin 
antibiotic treatment per institutional guidelines
Presence of significant bleeding events 
with or without thrombocytopenia , such as:
• Grade 3 or 4 hemorrhage
• Any grade serious hemorrhage event
• Any grade intracranial hemorrhage or 
hematomaDiscontinue acalabrutinib
Grade 4 platelet count decrease
(< 25,000/mm3)• Hold acalabrutinib and consider platelet 
transfusion s, as clinically indicated
• If thrombocytopenia has improved to ≤Grade 2 
within 3 days of event onset, restart acalabrutinib
• If thrombocytopenia has notimproved to 
≤Grade 2 within 3 days of event onset, 
discontinue acalabrutinib
Gastrointestinal/hepatic
Grade 3 or 4 nausea, vomiting, or diarrhea, 
if persistent despi[INVESTIGATOR_403409]/or antidiarrheal therapyDiscontinue acalabrutinib
Clinical Study Protocol -5.0 [COMPANY_008]
Acalabrutinib -D822FC00003
CONFIDENTIAL AND PROPRIETARY 45of 103Event Acalabrutinib Dose Modification /Discontinuation
Acute hepatic toxicity or hepatic failure, 
which is of such severity that after 
evaluation by a hepatologist, would 
consider appropriate to stop all non -
essential medicationsDiscontinu e acalabrutinib
Cardiovascular
Grade 3 or 4 hypertension , if persistent 
despi[INVESTIGATOR_913344] 3 or 4 arrhythmias that are sustained
orassociated with cardiovascular 
instabilityDiscontinue acalabrutinib
Infections
Sever e opportunistic infection (such as 
Pneumocysti sjirovecii pneumonia, 
toxoplasmosis, disseminated 
Mycobacterium avium complex , PML )Discontinue acalabrutinib
Grade 3 confirmed bacterial infections • Hold acalabrutinib
• Ifinfection does not respond to appropriate 
antimicrobial therapy within 48 -72 hours, 
discontinue acalabrutinib
Grade 4 con firmed bacterial infections Discontinue acalabrutinib
Other
Any non -COVID -19-related Grade 4 AE Discontinue acalabrutinib
Any other Grade 3 or Grade 4 toxicity that 
persists despi[INVESTIGATOR_913345] = adverse event; ALT = alanine aminotransferase; ANC = absolute neutrophil count; ALP = alkaline 
phosphatase; AST = aspartate aminotransferase ; G-CSF = granulocyte colon y-stimulating factor; 
PML =progressive multifocal leukoencephalopathy.
Clinical judgment should be used to determine appropriate management of the subject during 
any AE. 
Acalabrut inib may be held for a maximum o f 3 consecut ive days (6 consecutive doses) from 
expected dose due to toxicit y. Any other clinically  important events where dose delays may be 
considered appropriate by  [CONTACT_11856] , as well as continuat ion of t herapy after a dose i s 
held beyo nd [ADDRESS_1283444] receives a 
maximum o f 20doses of study  drug, even if this is b eyond the 10 -day dosing period.
Clinical Study Protocol -5.0 [COMPANY_008]
Acalabrutinib -D822FC00003
CONFIDENTIAL AND PROPRIETARY 46of 1036.7.1 Renal Impair ment
After administration of a single 100 mg radio labeled acalabrut inib dose in healt hy subjects, 
84% of the dose was recovered in the feces and 12% of the dose was recovered in the urine 
(2% acalabrut inib). No clinically relevant PK difference was observed in subjects with mild or 
moderate renal  impai rment (estimated glo merular filtration rate [eGFR] ≥30 mL/min/1.[ADDRESS_1283445] imated by [CONTACT_913383] [MDRD] equation). Acalabrut inib PK 
and clinical safet y has not been evaluated in subjects with severe renal impairment (eGFR 
<29mL/min/1.[ADDRESS_1283446]) or renal impairment requiring dialysis. 
The effect of dialysis on acalabrutinib plasma concentrations has not been studied. 
Acalabrut inib is rapi[INVESTIGATOR_638262], m etabo lised and distributed. The plasma protein binding is 
97.5% and is noncovalent (potentially dialyzable).  
 
 If subjects with 
COVID -19 enrolled in this study  requi re acute hem odialysis, i t is recommended to dose 
acalabrutinib 100 mg and pause hemodialysis for 2 to 4hours after acalabrutinib 
administration to allow for absorption and distributio n to target cell populat ions.
6.7.2 Hepatic Impair ment
Acalabrut inib clinical safet y has not been evaluated in pat ients with severe hepat ic 
impairment. If acalabrutinib is administe red to subjects with hepat ic impairment, monitor 
subjects carefully for AEs and fo llow recommendati on dose m odificat ions in Section6.7.
The PK acalabrut inib in subje cts wi th hepat ic impairment has been studied. Briefly, the AUC 
of acalabrutinib increased 1.9 -fold in subjects wi th mild hepat ic impairment (Child- Pugh 
classA), 1.5 -fold in subjects with moderate hepat ic impairment (Child -Pugh class B) and 
5.3-fold in sub jects with severe hepat ic impairment (Child- Pugh class C) compared with 
subjects wi th normal  liver funct ion. No clinically relevant PK difference in ACP -5862 was 
observed in subjects with severe hepat ic impairment (Child- Pugh class C) compared with 
subject s with normal  liver funct ion. No clinically relevant PK differences in acalabrutinib and 
ACP -5862 were observed in subjects with mild or moderate hepat ic impairment (total 
bilirubin less and equal to ULN and AST greater than ULN, or total bilirubin greater than 
ULN and any AST) relat ive to subjects with normal hepat ic function (total  bilirubin and AST 
within ULN).
6.[ADDRESS_1283447] 
WITHDRAWAL 
7.1 Discontinuation of Study Treatment 
Subjects may discont inue study  treatm ent for the foll owing reasons:
Unable to swallow pi[INVESTIGATOR_3353]
Com pleted treatm ent
Pregnancy
AE
Invest igator ’sdecision
Subject’s withdrawal o f consent from study
Decisio n by [CONTACT_913384]
Lost to follow -up
Death
Other
The Investi gator shoul d instruct the subject to contact [CONTACT_913385]. A subject that decides to discontinue study  treatm ent will always be 
asked about the reason(s) and the presence of any AEs. T he date of last intake of study  
treatm ent shoul d be docum ented in the eCRF. Refer to the guidance in Sect ion 6.5.3 .
All subjects will be fo llowed through 90(± 7) days after randomization.
Subjects who receive acalabrutinib should have fo llow up assessments for safet y 28 (± 3) days 
after the l ast dose of acalabrut inib (whether due to discontinuat ion or com pletion of dosing). 
Subjects who have been rando mized to the BS C arm shoul d have a fo llow up assessment for 
safet y 38 (± 3) days after randomizat ion.
For the safet y and survival fo llow-up visi ts, telemedicine is recommended for capturing AEs 
and conco mitant m edicati ons. Safet y laboratory  tests can be done at the hospi [INVESTIGATOR_6879] a l ocal 
laboratory  provi ded the resul ts are ul timately captured in the clinical database for the study .
7.[ADDRESS_1283448] m ay withdraw from  the study  (eg, wi thdraw consent), at any  time (investigational 
product andassessme nts) at hi s/her own request, without prejudice to further treatment.
A subject who considers withdrawing fro m the study  must be inform ed by  [CONTACT_103445] m odified fo llow-up opti ons (eg, tel ephone contact, a contact [CONTACT_4490] a relative or treating 
phys ician, or informat ion from medical records).
Clinical Study Protocol -5.[ADDRESS_1283449] withdraws fro m the study , he/she m ay request destructi on of  any samples taken, 
and the Investi gator must document this in the site study records.  
A subject who withdraws consent will always be asked about the reason(s) and the presence of 
any AE. The Invest igator will follow up sub jects as medically indicated . 
7.[ADDRESS_1283450] to follow -up if he /she fails to return for scheduled visit s or is 
unable to be contact[CONTACT_17066].
In the case a subject is lost to fo llow-up, every  possible effort must be made by  [CONTACT_913386]. Site personnel 
shoul d check hospi [INVESTIGATOR_239158] a publicly  available death regi stry (if available), as well as 
checking wit h the subject’s current physician, to obtain a current survival status. The m easures 
taken to fo llow up m ust be docum ented (the applicable eCRF modules will be updated) .
When a subject withdraws before complet ingthe study , the reason for withdrawal must be 
docum ented in the eCRF and in the source documents. Subjects who withdraw consent should 
still be encouraged to complete the SFU assessments before withdrawing consent, but these 
assessments cannot be mandated once consent is wit hdrawn.
Subjects who are withdrawn or removed fro m study  treatm ent will  not be repl aced.
8. STUDY ASSESSMENTS AND PROCEDURES
Study  procedures and their timing are summarised in the SoA in Section1.1.
The Investi gator will ensure that data are recorded on the eCRF. 
The Investi gator ensures the accuracy, completeness, and timeliness of the data recorded and 
of the provisio n of answers to data queries per the Clinical Study  Agreement. The Investigator
will sign the completed eCRF. A copy  of the com pleted eCRF will be archived at the study  
site.
Immediate safet y concerns should be discussed wit h the Medical Monitor upon occurrence or 
awareness to determ ine if the subject should continue or discont inue study  treatment.
Adherence to the study  design requi rements, including those specified in the SoA, is essent ial 
and required for study  conduct.
Clinical Study Protocol -5.[ADDRESS_1283451]’s clinical management of COVID -[ADDRESS_1283452] itutional guidelines 
(Appendix A3).
8.1.[ADDRESS_1283453] demographics will be collected: age, sex, race ,ethnicit y,and history  of 
substance abuse ( cigarettes [ yes/no; if yes, specify packs per day ], vapi[INVESTIGATOR_007] [yes/no] , 
recreati onal drugs [yes/no; if yes, specify  name], alcohol [yes/no; if yes, specify amount] ).
8.1.[ADDRESS_1283454]’s relevant m edical history  through revi ew of  medical records 
and by  [CONTACT_30230]. Concurrent medical signs and symptoms must be documented to establish 
baseline severit ies. Informat ion on COVID -[ADDRESS_1283455], or 
any other appropriate means to confirm pneum onia prior to or upon hospi [INVESTIGATOR_3094](within 
7days of randomizat ion). Post treatm ent assessment will cont inue as clinically indicated .
A single 12-lead ECG and will be done during the screening period and at Day [ADDRESS_1283456] an 
arteri al blood gas ob tained.
8.1.7 Urine or Serum Pregnancy 
Screening pregnancy  testing will  be done on wom en of childbearing potential only (refer to 
Appendix F).
8.1.8 Laboratory Tests
The screening period should occur immediately prior to randomization and dosing. Screening 
can be performed within 1 to 3 days prior to dosing, depending on the local requi rements for 
laboratory  turn -around times. The following laboratory  tests will be done during screening as 
specified in the SoA (Secti on1.1)using the sites local laboratories:
Urine or serum pregnancy test (women of childbearing potential only)
Hem atology studi es must include complete blood count (CBC) with different ial 
including, but not limited to white blood cell count, hemoglobin, platelet count, ANC or 
percentage, red bl ood cell count, absolute monocy te count or percentage , and abso lute 
lymphocy te count (ALC) or percentage . 
Chemistry  will include albumin, alkaline phosphatase, ALT, AST, bicarbonate, blood 
urea nitrogen (BUN), calcium, chloride, creatinine, glucose, lactate dehy drogenase 
(LDH), m agnesium , phosphate/phosphorus, potassium, sodium, total bilirubin (direct and 
indirect bilirubin, if available) , total  protein, and uric acid.  
Clinical Study Protocol -5.0 [COMPANY_008]
Acalabrutinib -D822FC00003
CONFIDENTIAL AND PROPRIETARY 51of 103Arterial blood gases (if available; see Section 8.4.1 )
C-reactive protein (CRP)
Serum  ferritin, fibrinogen, D -dimer, procalcitonin
Prothrombin t ime(PT), activated partial thro mboplastin t ime ( aPTT ), internat ional 
norm alized rati o (INR)
Cardi ac troponin I
Hepati tis serol ogymust include, at a minimum, HBsAg, ant i-HBc, and HCV ant ibody  (if 
additional hepati tis serol ogy is collected per inst itutional guidelines, i t shoul d be collected 
in the database)
SARS -CoV -[ADDRESS_1283457] . Sites should 
report thi s as posi tive/negat ive.
Refer to the laboratory  manual  for instructi ons on processing and shippi[INVESTIGATOR_007]. Addit ional 
handling information provided in Appendix C.
8.2 Concomitant Medications
Docum ent all  concomi tant m edicat ions and procedures fro m the start of screening procedures 
through the end of participat ion on the study  (refer to Section 1.1).Reason for treatment 
shoul d be captured as “disease under study ”.
Medicat ions used as BSC shoul d be captured as conco mitant m edicat ions.
8.3 On-study Procedures 
Planned t ime po ints for all on -study  procedures are provided in the SoA ( Secti on1.1). While 
the subject remains hospi[INVESTIGATOR_057], assessments should be performed per SoA until discharge. 
The date of admissio n and di scharge will be collected for all subjects. If a subject is 
discharged pri or to Day  10, the subject should continue to take acalabrut inib at ho me.If the 
subject was discharged prior to Day  7, the subject should retu rn to the clinic 2 to 4 days after 
discharge and co mplete the Day  10 assessment as outlined in the SoA.
The fo llowing l aboratory  evaluati ons will  be done at the l ocal laboratori eswhile on study :
Urine or serum pregnancy test (women of childbearing potenti al only)
Hem atology studi es must include complete blood count (CBC) with different ial 
including, but not limited to white blood cell count, hemoglobin, platelet count, ANC or 
percentage, red blood cell count, absolute monocy te count or p ercentage, and absolute 
lymphocy te count (ALC) or percentage.
Chemistry  will include albumin, alkaline phosphatase, ALT, AST, bicarbonate, BUN, 
calcium, chloride, creatinine, glucose, LDH, magnesium, phosphate/phosphorus, 
potassi um, sodi um, total  bilirubin (direct and in direct bilirubin, if available) , total  protein, 
and uric acid.
Clinical Study Protocol -5.0 [COMPANY_008]
Acalabrutinib -D822FC00003
CONFIDENTIAL AND PROPRIETARY 52of 103Arterial blood gases (if available; see Section 8.4.1 )
CRP
Serum  ferritin, fibrinogen, D-dimer, procalcitonin *
PT, aPTT, INR *
Cardi ac troponin I *
Hepati tis B sero logy will be collected as clinically  indicated for subjects with a known 
history  of hepat itis B exposure (see Secti on 6.6.3 )
*These laboratory  tests shoul d be perform ed m ore frequently than described in the SoA 
(Secti on1.1) if clinically indicated.
Samples ( peripheral bl ood sam ples for m ononuclear cells, serum/plasma, and RNA ) will  be 
collected per the timepo ints delineated in the SoA (Secti on1.1)and sent to respective central 
laboratories for the fo llowing tests:

  
Immunophenoty pi[INVESTIGATOR_007]: Fl ow cy tometry testing of peripheral blood will include, but is not 
limited to, CD3+, CD4+, CD8+, CD14+, CD19+ and CD16+/56+ cells
Serum  and na sal swab samples for SARS -CoV -2 viral load/viral shedding 
  
Plasma sam ples f or acalabrutinib/ACP-5862 PK (subjects on acalabrut inib arm only)

NOTE: Safet y, CRP, PK, PD, and correlat ive laboratory  tests are consi dered Ti er [ADDRESS_1283458] follow the SoA.
Refer to the laboratory  manual  for instructi ons on processing and shippi[INVESTIGATOR_007]. Addit ional 
handling information provi ded in Appendix C.
Other procedures to be performed while on study  include:
Chest imaging
ECG
Echocardi ogram
Vital signs
CCI
CCI
CCI
CCI
Clinical Study Protocol -5.[ADDRESS_1283459] ion of inspi[INVESTIGATOR_1401] (FiO2).
If a subject requires mechanical vent ilation, data will be recorded regarding whether vent ilator 
weaning was attempted. 
For subjects on mechanical vent ilation the fo llowing ventilator settings will be recorded: tidal 
volume, FiO2, peak airway  pressure ove r the l ast [ADDRESS_1283460] value of 
the day will be entered
For subjects on mechanical vent ilation, an arterial blood gas (pH, partial pressure of oxygen 
[PaO2], partial pressure of carbon dio xide [ PaCO 2],and FiO 2at the time the sample was 
obtained), will be recorded qd. If more than one value is obtained for the arterial blood gases , 
the value closest to 08:00 will be used.
Arterial gasses shoul d be co llected fro m subjects if the sample is easily  accessible and the 
procedure will not be painful to subjects (ie, subject is in the ICU or has arterial port). All 
available data fro m the arterial gases should be entered into the database. If the collect ion of 
arteri al gases is not clinically indicated, the test should not be performed.
Predi cted body  weight will be recorded on the ventilator eCRF for assessment of tidal vo lume.
8.4.2 Modified Sequential Organ Failure Assessment (SOFA) Scores
A modified SOFA score will be calculated. For each of the fo llowing routine assessments, the 
worst val ue of the day  will be recorded in the eCRF: PaO 2/FiO2(mmHg) or oxy gen saturati on 
by [CONTACT_406]  (SpO 2)/FiO2(mmHg), platelet count, bilirubin, vasopressor use (μ g/kg/min, 
mmHg), and creatinine ([or urine output]). For laboratory values, use last available (if wit hin 
48 hours). On day s when laboratory  resul ts are unavailable, values will be extrapolated from 
the previously  available values.
8.4.[ADDRESS_1283461] care (or equivalent) on each day during hospi[INVESTIGATOR_913346]  90. In the event of an affirmat ive response, a further question will be asked to 
determine if this ICU care is considered necessary  (rather than being due to logist ical reasons).
Only days in the ICU (or equivalent), which the Investi gator considers necessary, will be 
regarded as ICU days.
Clinical Study Protocol -5.[ADDRESS_1283462] ion.
The definit ions of an AE or SAE can be found in Appendix B.
The fo llowing are NOT considered an AE:
Pre-existing condition that has not worsened: A pre -existing condit ion (documented on 
the medical history  eCRF) is not considered an AE unless the severit y, frequency , or 
character of the event worsens during the study  period.
Diagnostic testing and procedures: Testing and procedures should not be reported as 
AEs or SAEs, but rather the cause for the test or procedure should be reported. If a test or 
procedure is done to rule out a diagnosis, the sign or symptom leading to the 
test/procedure should be the event term, and the event term should only be updated to the 
diagnosis if/when the diagnosis is confirmed. Testing and procedures performed solely as 
screening measures (eg, routine screening mammo graphy  or col onoscopy ) shoul d not be 
reported as AEs or SAEs.
Abnormal laboratory results: Abnorm al laboratory  resul ts are not AEs unless they  are 
clinically significant. For example, a clinically significant laboratory  resul t is one that 
requi res treatm ent (f or exam ple a bl ood transfus ion for low haem oglobin) or requi res a 
change in study  drug (eg, l owering the dose or withho lding study  drug while the 
laboratory  finding reso lves or stabilizes).
Progression of underlying disease: Progression of underlying disease unequivocally 
related to COVID -19 pneumonia (such as worsening of respi[INVESTIGATOR_82219] o r
complicat ions associated with pneumo nia) will not be reported as an AE if it is clearly 
consistent with the suspected progression of the underlying disease. Clinical symptoms of 
progression ma y be reported as AEs if the symptoms cannot be determined as exclusively 
due to the progression of the underlying disease, or if they do not fit the expected pattern 
of progressi on for the disease under study .
Symptom atic deteri oration m ay occur in so me subjects. Symptomat ic deterioration is when 
progression is evident in the subject’s clinical symptoms and the Invest igator may elect not to 
perform  further di sease assessments. 
If there is any uncertaint y about an AE being due only to the disease under study, it should be 
reported as an AE or SAE.
AE will be reported by  [CONTACT_423] (or, when appropriate, by  a caregiver, surrogate, or the 
subject's legally  authori zed representative).
Clinical Study Protocol -5.0 [COMPANY_008]
Acalabrutinib -D822FC00003
CONFIDENTIAL AND PROPRIETARY 55of 103The Investi gator and any desig nees are responsible for detecting, document ing, and recording 
events that meet the definit ion of an AE or SAE. For informat ion on how to fo llow up AEs ,
see Secti on8.6.3 .
8.6.1 Method of Detecting AEs and SAEs
Care will be taken not to introduce bias when detecting AEs and/or SAEs. Open -ended and 
non-leading verbal quest ioning of the subject is the preferred method to inquire about 
AEoccurrences.  
8.6.[ADDRESS_1283463] be reported. After randomization , all AEs/SAEs, 
irrespect ive of attribut ion of causalit y, must be reported. 
AE reporti ng, irrespective of seriousness, ends 28(± 3) days after the last dose of study 
treatm ents(s) for those on acalabrut inib+ BSC (Arm 1) and 38 (± 3) day s from rando mizat ion 
for those on BSC only (Arm 2).
SAEs considered related to study  treatm ents(s) or study  procedures occurring after the end of 
the AE reporting period (as defined above) must be reported.  Informat ion on concomitant 
medicat ions at the time of the treatment -related SAE will also be collected.
All SAEs will be recorded and reported to the Sponsor or designee within 1day (i e, 
immediat ely but no later than 24 hours from when he or she beco mes aware of it) , as 
indicated in Appendix B. The Investi gator will submit any updated SAE data to the Sponsor
within 24 hours of it being available.
The m ethod of recording, evaluat ing, and assessing causalit y of AE and SAE and the 
procedures for reporting SAEs are provided in Secti on8.7.1 .
8.6.3 Follow -up of AEs and SAEs
After the init ial AE/SAE report, the Invest igator is required to proactively fo llow each subject 
at subsequent visits/contacts. All SAEs/non -SAEs/AEs of special interest (AESIs ; as defined 
in Secti on8.6.12 ), will be fo llowed until reso lution, stabilization, the event is otherwise 
explained, or the subject is lost to fo llow-up. 
Any AEs that are unresolved at the subject’s l ast AE assessment or other assessment/visit as 
appropriate in the study  are f ollowed up by [CONTACT_913387], 
but without further recording in the eCRF. The Sponsor retains the right to request addit ional 
inform ation for any subject with ongoing AE(s)/SAE(s) at the end of the study , if judged 
necessary .
Clinical Study Protocol -5.0 [COMPANY_008]
Acalabrutinib -D822FC00003
CONFIDENTIAL AND PROPRIETARY 56of 1038.6.4 Adverse Event Data Collection
The following variables will be collected for each AE:
AE di agnosis/descri ption
The date when the AE started and stopped
Maximum Commo n Termino logy Criteria f or Adverse Events ( CTCAE )grade
Whether the AE is serious or not
Invest igator causalit y rating against the invest igational product (yes or no)
Action taken regarding invest igational product
Administrati on of  treatm ent for the AE 
Outcom e
In addit ion, the fo llowing vari ables will be collected for SAEs:
Date AE m et cri teria for SAE
Date Invest igator became aware of SAE
Seriousness criteria
Date of hospi[INVESTIGATOR_72913]
Date of discharge
Probable cause of death
Date of death
Autopsy  performed
Causalit y assessment in relat ion to study  procedure(s)
Causalit y assessment to other medicat ions
Descript ion of SAE
The grading scales found in the revised NCI CTCAE Version 5.0 will be ut ilized for all events 
with an assigned CTCAE grading. For those events without assigned CTCAE grades, the 
recommendat ion in the CTCAE criteria that converts mild, moderate, and severe events into 
CTCAE grades should be used. A copy  of the CTCAE Versio n 5.0 can be downloaded fro m 
the Cancer Therapy Evaluat ion Program  website 
(https://ctep.cancer.gov/protocolDevelopment/electronic_applicat ions/docs/CTCAE_v5_Quic
k_Reference_8.5x11.pdf ).
8.6.[ADDRESS_1283464] and each AE, 
andanswer ‘yes’ or ‘n o’ to the questi on ‘Do y ou consi der that there is a reasonable possibilit y 
that the event may have been caused by  [CONTACT_33159]?’
Clinical Study Protocol -5.0 [COMPANY_008]
Acalabrutinib -D822FC00003
CONFIDENTIAL AND PROPRIETARY 57of 103For SAEs, causal relat ionship will also be assessed for other medicat ion and study  procedures. 
Note that for SAE s that could be associated with any study  procedure the causal relationship is 
implied as ‘yes’.
A guide to the interpretation of the causalit y quest ion is found in Appendix Bof this protocol .
8.6.[ADDRESS_1283465] or reported in response to the open question 
from the study  site staff: ‘Have you had any health problems since the previous visit/you were
last asked?’ , or revealed by [CONTACT_33145]. When 
collect ing AEs, the recording of diagnoses is preferred (when possible) to recording a list of 
signs and symptoms. However, if a diagnosis is known and there are other si gns or symptom s 
that are not generally part of the diagnosis, the diagnosis and each sign or symptom will be 
recorded separately.
8.6.7 Adverse Events Based on Examinations and Tests
The results from the protocol -mandated laboratory tests and vital signs will be summarised in 
the Clinical Study  Report . Deteri oration as com pared to baseline in protocol -mandated 
procedures (eg, safet y laboratory  tests and vi tal signs) shoul d therefore only be reported as 
AEs if they  fulfil any  of the SAE cri teria or are the reason for discont inuat ion of treatment 
with the invest igational product.
If deteri oration in a laboratory  value/vi tal sign i s associ ated wi th clinical signs and symptoms, 
the sign or symptom  will be reported as an AE and the associated laboratory  resul t/vital sign 
will be considered as addit ional informat ion. Wherever possible the reporting Invest igator
uses the clinical, rather than the laboratory  term  (eg, anemia versus low hemoglobin value). In 
the absence of cl inical  signs or symptom s, clinically  relevant deteri orations in non -mandated 
param eters shoul d be reported as AE(s).
Deteri oration of  a laboratory  value, which is unequivocally due to disease progression, should 
not be reported as an AE/SAE.
Any new or agg ravated clinically relevant abnormal medical finding at a physical examinat ion 
as com pared wi th the baseline assessment will be reported as an AE unless unequivocally 
related to the disease under study , see Secti on 8.6.9 and Secti on 8.6.10 .
8.6.8 Hy’s Law
Cases where a subject shows elevat ions in liver biochemistry  may require furt her evaluat ion, 
and occurrences o f AST or ALT ≥3×ULN together with total bilirubin ≥2×ULN may need to 
be reported as SAEs. Please refer to Appendix Dfor further inst ruction on cases of increases 
in liver bio chemistry  and evaluat ion of Hy’s law.
Clinical Study Protocol -5.[ADDRESS_1283466]’s condit ion attributable to 
COVID -[ADDRESS_1283467] is being studied.  It may be an 
increase in the severit y of the di sease under study  and/or increases in the symptom s of the 
disease. Events, which are unequivocally  due to COVID -[ADDRESS_1283468] be reported as 
follows:
Death cl early  resul ting fro m disease progressi on shoul d be docum ented in the eCRF in 
the Death page. It should not be reported as an SAE.
Where death is not due (or not clearly  due) to progressio n of the disease under study , the 
AE causing the death must be reported as an SAE within 24 hours. It should also be 
docum ented in the Death page in the eCRF. The report should contain a comment 
regarding the co -involvement of disease progression, if appropriate, and should assign the 
main and contributory  causes of death.
Deaths with an unknown cause shoul d always be reported as an SAE and documented in 
the Death page in the eCRF, but every  effort should be m ade to determine a cause of 
death. A post -mortem may be helpful in the assessment of the cause of death, and if 
perform ed, a copy  of the post-mortem resul ts should be forwarded to Sponsor Patient 
Safety or its representative wit hin the usual t ime frames.
Deaths occurring after the protocol -defined fo llow-up period after the administration of the 
last dose of study  treatm ent shoul d be docum ented in the Death page. If the death occurred as 
a resul t of an event that started after the defined follow -up peri od and the event is considered 
to be due to a late -onset toxicit y to study  treatm ent, then i t shoul d also be reported as an SAE.
8.6.[ADDRESS_1283469] be reported to 
the Sponsor expedit iously (see Section8.7.1 for reporting instructions), irrespect ive of 
regulatory  seriousness cri teria or causalit y:
Ventricular arrhythmias (eg, ventri cular extrasy stoles, ventri cular tachycardia, 
ventri cular arrhy thmia, ventri cular fibrillat ion)
8.[ADDRESS_1283470], or to the study  procedure(s). All SAEs will be recorded in the eCRF. 
Prom pt notificat ion by [CONTACT_913388] l egal 
obligat ions and ethical responsibilit ies towards the safet y of subjects and the safet y of a study  
treatm ent under clinical invest igation are met. 
The Sponsor has a legal responsibilit y to notify  both the l ocal regulatory  authori tyand other 
regul atory  agencies about the safet y of a study  treatm ent under clinical invest igation.  The 
Sponsor will co mply with country -specific regulatory  requi rements relating to safet y reporti ng 
to the regulatory  authori ty, the Institutional Review Boa rd (IRB)/Independent Ethics 
Committee ( IEC), and Invest igator s.
If any SAE occurs in the course of the study , then Invest igator s or other site personnel inform 
the appropriate Sponsor representatives within 1 day (ie, immediately but no later than 
24hours from when he or she beco mes aware of it).
The designated Sponsor representative works with the Invest igator to ensure that all the 
necessary  informat ion is provided to the Sponsor Patient Safet y data entry  site within 
1calendar day of initial receipt for fatal and life -threatening events and within [ADDRESS_1283471] igator s or other si te personnel inform Sponsor
representatives of any  follow-up inform ation on a previously reported SAE within 1 calendar 
day (ie, immediately but no later than 24 hours from when he or she beco mes aware of it).
For all studies except those utilizing medical devices, Invest igator safet y reports m ust be 
prepared for suspected unexpected serious adverse reactions (S[LOCATION_003]R) according to local 
regul atory  requi rements and Sponsor policy and forwarded to Invest igator s as necessary.
Clinical Study Protocol -5.[ADDRESS_1283472] igator who receives an Investigator safety report describing an SAE or other specific 
safet y informat ion (eg, summary  or list ing of SAEs) fro m the Sponsor will review and file the 
report/information wit h the Invest igator ’sBrochure and will notify the IRB/IEC according to 
local req uirements, if appropri ate.
For further guidance on the definit ion of a SAE, see Appendix B.
8.7.2 Pregnancy
All pregnancies, partner pregnancies, and outcomes of pregnancy/partner pregnancy should be 
reported to the Sponsor , with the except ion of any  pregnancy that i s discovered before the 
subject has received any study  treatm ent.
If a pregnancy  is reported, the Invest igator shoul d inform  the Sponsor within 1 day  (ie, 
immediately  but no l ater than 24 hours of when he/she becomes aware of the pregnancy) .
Abnorm al pregnancy outcom es (eg, spontaneous abortion, fetal death, stillbirth, congenital 
anomalies, ectopi c pregnancy ) are considered SAEs.
[IP_ADDRESS] Maternal Exposure
If a subject beco mes pregnant during the course of the study, invest igational product should be 
discontinued immediately .
Pregnancy itself is not regarded as an AE unless there is a suspi[INVESTIGATOR_24510] n that the invest igational 
product under study  may have interfered with the effectiveness of a contraceptive medicat ion. 
Congenital abnormalit ies/birth defects and spontaneous miscarriages should be reported and 
handled as SAEs. Elective abortions without complicat ions sho uld not be handled as AEs. The 
outcom e of all pregnancies (spontaneous miscarriage, elective terminat ion, ectopic pregnancy, 
norm al birth, or congenital abnormalit y) should be fo llowed up and docum ented even if the 
subject was discont inued from the study.
If any pregnancy  occurs in the course of the study , then the Invest igator or other si te personnel 
informs the appropriate Sponsor representatives within 1 day (ie, immediately but no later 
than 24 hours of when he/she beco mes aware of the pregnancy).
The d esignated Sponsor representative works with the Invest igator to ensure that all relevant 
inform ation is provided to the Sponsor subject safety data entry site within eit her 1 day  or 
5calendar days for SAEs (see Secti on8.7.1 ), and within [ADDRESS_1283473]’s partner is not considered to be an AE. However, the outcome o f all 
pregnancies (spontaneous miscarriage, elect ive terminat ion, ectopic pregnancy, normal bi rth, 
or congenital abnormalit y), occurring from the date of the first dose until [ADDRESS_1283474] ’s partner. The local study  team  shoul d 
adopt the Master Pregnant Pa rtner Form in line with local procedures/requirements and submit 
it to the rel evant regulatory  authori ty/IRB/ethics commi ttee pri or to use.
8.7.[ADDRESS_1283475] administration of study  treatm ent shoul d be 
recorded on the Adverse Event eCRF. If the associated AE fulfils serious criteria, the event 
shoul d be reported to the Sponsor immediately (ie, no later than 24 hours after le arning of the 
event). 
For overdoses associated with a SAE, the standard reporting t imelines apply; see 
Secti on8.6.[ADDRESS_1283476] igator (or other site 
personnel) informs the appropriate Sponsor representatives within 1 day (ie, immediately but 
no later than [ADDRESS_1283477] igator (or other site personnel) beco mes aware of the 
error.
The designated Sponsor representative works with the Invest igator to ensure that all relevant 
inform ation is completed within 1 calendar day (in the event of init ial fatal/life-threatening 
errors or fo llow-up fatal/life-threatening errors) or 5 calendar days (in the event of other 
Clinical Study Protocol -5.0 [COMPANY_008]
Acalabrutinib -D822FC00003
CONFIDENTIAL AND PROPRIETARY 62of 103serious ini tial and f ollow-up errors) if there is an SAE associated with the medicat ion error 
(see Secti on8.7.1 ), and within [ADDRESS_1283478] in the study will be 
assessed using a 9 -point category  ordinal  scale below .Assessments will be performed as 
described in the SoA .
0.* Uninfected, no clinical or viro logical evidence of infect ion 
1. Ambulatory , no limitation o f activit ies 
2. Ambulatory , limitat ion of act ivities 
3. Hospi[INVESTIGATOR_277297] –mild disease, no oxygen therapy 
4. Hospi[INVESTIGATOR_277297] –mild disease, oxygen by [CONTACT_88543] 
5. Hospi[INVESTIGATOR_277297] –severe disease, non -invasive vent ilation or high flow oxygen 
6. Hospi[INVESTIGATOR_15583] –severe disease, intubat ion and m echanical vent ilation 
7. Hospi[INVESTIGATOR_277297] –severe disease, vent ilation and addi tional organ support , such 
aspressors, renal replacement therapy , extracorporeal membrane 
oxygenat ion 
8. Death 
*Score of zero on 9 -point category ordinal scale will not be evaluated in this study .
To be considered a “responder” to treatment with a target candidate, a subject needs to show 
an improvement of at least 2 points (fro m rando mization) on thi s scale . The time to clinical 
improvement of 2 points will be assessed as a secondary  endpoint.
9. STAT ISTICAL CONSIDERATIONS 
9.1 Statistical Hypotheses
Overall study  design is described in Section 4.1of the protocol. Subjects who are hospi[INVESTIGATOR_573815] -19 symptom s and meet the eligibilit y criteria will  be randomized 1:1 to receive 
acalabrutinib plus BSC ( Arm 1: n=30) vs BSC ( Arm 2: n=30).
Stratificat ion by [CONTACT_654] ( ≥65 vs <65 y ears) and com orbidi ties (present vs absent) will be applied
to randomizat ion. 
Clinical Study Protocol -5.[ADDRESS_1283479] ive of the study  is to evaluate the safet y and preliminary  efficacy  of 
acalabrutinib plus BSC (Arm 1) vs BSC (Arm 2) . There i s no form al hypothesis testing for the 
safet y and efficacy endpo ints.The primary focus for the efficacy  is to estimate the tr eatment 
effect as measured by [CONTACT_913389][INVESTIGATOR_33078].
9.[ADDRESS_1283480] anned total  number of subjects in this study  is 60.  
Based on the reported rate of deaths and need for ICU admissio n (a surrogate for respi[INVESTIGATOR_36639]) in subjects who are hospi[INVESTIGATOR_191544] -19(Arentz et al 2020 , Bhatraj u et al  
2020 , CDC 2020 , Grasselli et al 2020 ), it assume d that the proportion of subjects who are 
alive and free of respi[INVESTIGATOR_647197]  28 is 70% under BSC . A targeted difference of 
20% between two treatment arms (ie ,90% for acalabrut inib + BSC) is of clinical  interest . 
With a total sample size of 60, the half -width of the 2-sided90% confidence interval for the
observed treatm ent difference is 16.4%using unpooled est imate for variance . It has 
approximately  64% power, wi th a 2-sided ty pe I error of 0.1,to detect a difference of 20% 
between the 2arms. 
9.3 Populations for Analyses
The analysis populat ions are defined as shown in Table 6.
Table 6 Analysis Populations
Population/ Analysis set Description
Full analysis set (ITT population) The full analysis set will include a ll subjects who 
are randomized and will be used for all efficacy 
analyses. Treatment arms will be compared on the 
basis of randomized study treatment, regardless of 
the tre atment actually received. Subjects who 
were randomized but did not subsequently go on 
to receive study treatment will be included in the 
analysis in the treatment arm to which they were 
randomized , following the “intent -to-treat” 
principle .
Per-protocol analysis set The per -protocol analysis set willbe a subset of 
the ITT population including only subjects 
without important detected protocol deviations 
affecting the efficacy endpoints. Subjects will be 
summari zed according to the actual treatment first 
received. The primary endpoint of the study will 
also be summarized for th is population.
Clinical Study Protocol -5.0 [COMPANY_008]
Acalabrutinib -D822FC00003
CONFIDENTIAL AND PROPRIETARY 64of 103Table 6 Analysis Populations
Population/ Analysis set Description
Safety analysis set The safety analysis set (Safety population) is 
based on the treatment subjects actually received.  
In this study, the treatment is either acalabru tinib 
+ BSC or BSC only. If a subject receives at least [ADDRESS_1283481] was randomized to. Subjects who are 
randomized to acalabrutinib + BS Cbutdo not 
receive a ny acalabrutinib will be summarized in 
the BSC group. 
PK analysis set The PK analysis set will include a ll subjects who 
receive ≥1 dose of acalabrutinib and had ≥[ADDRESS_1283482] and the statistician prior to 
any analyses being performed.
BSC = best supportive care; ITT = Intent -to-treat; PK = pharmacokinetic.
9.4 Interim Analysis
There areno formal interim fut ility and interim efficacy analyse sin this Phase 2 study .
9.5 Missing Data Handling
No im putati on of  values for missing data will be performed except that missing or partial start 
and end dates for AEs and conco mitant m edicati on will be imputed per prespecified, 
conservative imputation rules.
The specification for handling death in the analysis of endpoints that do not contain mortality as a 
component will be provided in the Statistical Analysis Plan (SAP).
9.[ADDRESS_1283483] been 
followed for 38 (±3) days fro m rando mizat ion.
An updated analysis for those endpoints requiring [ADDRESS_1283484] of monitoring and recording AEs, SAEs and AEs leading to 
discontinuat ion of study  treatm ent; m easurements of protocol -specified hematology , clinical  
chemistry , and other l aboratory  variables; measurement of protocol -specified vital signs; and 
other protocol -specified tests that are deemed crit ical to the safet y evaluat ion of the study  
treatm ent. All  safety  analyses will be performed on the safety  analysis set as defined in 
Secti on9.3.
Verbat im descriptions of AEs will be mapped per the most recent version of Medical 
Dictionary for Regulatory  Activities (MedDRA) thesaurus terms and graded per National 
Canc er Inst itute (NCI) CTCAE, v5.[ADDRESS_1283485] reported NCI CTCAE grade. TEAEs will be 
summarized, unless otherwise specified. In this study , for Arm  1 (acalabrutinib + BSC), 
TEAEs are defined as AEs starting or ongoing AEs worsening after the first dose of study  
treatm ent and AEs with start date up to the last dose of study  treatment pl us 28 (± 3) days; for 
Arm 2 (BSC only), TEAEs are defined as AEs starting or ongoing AEs worsening after the 
date of rando mizat ion and AEs with start date up to 38 (± 3) day s from rando mizat ion.
Laboratory  abnorm alities will  be defined based on laboratory  normal  ranges (universal normal 
ranges, if central lab oratory ). Sel ected l aboratory  param eters m ay be analysed wi th shift tabl es 
and summaries of changes fro m baseline to worst post -treatm ent val ue.
Vital sign and all other safet y assessments will be tabulated and summarized.
Full details o f AE, l aboratory  assessment s, vital sign assessment s and all other safet y 
assessments will be provi ded in the SAP.
9.6.2 Efficacy Analyses
Primary Endpoint
The primary endpo intisthe proporti on of  subjects who are alive and free of respi[INVESTIGATOR_628608]  28(see Section 3for a definit ion ofrespi [INVESTIGATOR_33078] ). The point estimate and its 
90%confidence interval (CI; using Wald method with continuit y correction ) will be 
calculated for each treatment arm. The Cochran -Mantel -Haenszel χ2 test stratified by [CONTACT_654] 
(≥65 vs < 65 y ears) and com orbidities (present vs absent) will be used to compare the 
proporti on of  subjects who are alive and free of respi[INVESTIGATOR_647197]  28between the two 
treatm ent arm s. An unstratified analysis will also be perform ed. Finally , the difference in the 
proporti on of  subjects who are alive and free of respi[INVESTIGATOR_647197]  28will also be 
Clinical Study Protocol -5.0 [COMPANY_008]
Acalabrutinib -D822FC00003
CONFIDENTIAL AND PROPRIETARY 66of 103provi ded wi th 90%CIs. The treatment difference will be also estimated using a logist ic 
regression ( Ge 2011 ) with indicators for treatment and the rando mizat ion stratificat ion factors 
(2 × 2) as well as baseline respi[INVESTIGATOR_33078] (withvs without).
The primary  endpoint of the study  will be summarized by  [CONTACT_913390], 
sex, race, ethnicit y, com orbidities, baseline respi[INVESTIGATOR_33078] , and history  of substance abuse .
The primary  endpoint will be summarized and analysed as per the methods above for the full 
analysis set (ITT population) as well as the per -protocol analysis set.
Addit ional sensit ivity analyses and subgroup analyses of theprimary  endpoint may  be 
perform ed as appropri ate.
Secondary Endpoints
The proporti on of  subjects alive and free o f respi [INVESTIGATOR_647197]  14will be summarized 
using the full analysis set.
Summary  statistics (n, m ean, median, standard deviat ion, minimum, and maximum) will be 
presented by [CONTACT_913391](refer to Section 3).
Summary  statistics for the number of days hospi[INVESTIGATOR_913347] [ADDRESS_1283486] occurrence of respi[INVESTIGATOR_913348]  (up to 
28days after randomization) due to any  cause will be analysed using Kaplan -Meier m ethod; 
hazard ratio and corresponding 90% CIs will be estimated using Cox proportional hazards 
models, stratified by  [CONTACT_913392]. If a subject did not have an event 
and did not drop out prior to Day  28, the data will be censored at D ay 28; if a subject did not 
have an event but dropped out prior to Day  28, the data will be c ensored at the l ast date known 
to be alive and free of respi[INVESTIGATOR_33078].
Similarly, time to clinical improvement of at least 2 points (from rando mization) on a 9 -point 
category  ordinal scale through Day  28 will be analysed using Kaplan -Meier m ethod.
Thestatistical analysis plan will provi de the further details.
9.6.3 Pharmacokinetic and Pharmacodynamic Analys es 
PK assessments will be conducted in up to 15 evaluable subjects and PD assessments in up to 
15evaluable subjects rando mized to Arm 1 (acalabrutinib + BSC). Subjects are considered 
evaluable if they have an evaluable PK/PD profile, ie,(1) receive acalabrutinib treatment and 
(2) do not have data that are unavailable or inco mplete ( ie,provi de data from  all PK/PD visi ts 
indicated in the SoA).
Clinical Study Protocol -5.[ADDRESS_1283487] ics and 
Outcom es of  21 Cri tically  Ill Patients Wi th COVID -19 in Washington State. JAMA. 2020.
Bhatraj u PK, Ghassemieh BJ, Nicho ls M, Kim R, Jerome KR, Nalla AK et al. Covid -19 in 
Critically  Ill Patients in the Seattl e Regi on -Case Series. N Engl J Med. 2020;382(21):2012 -
22.
Buggy  JJ, Elias L. Bruton ty rosine kinase (BTK) and i ts rol e in B -cell malignancy . Int Rev 
Immunol. 2012;31(2):[ADDRESS_1283488] JC, Harrington B, O'Brien S, Jones JA, Schuh A, Devereux S et al. Acalabrutinib (ACP -
196) in Relapsed Chronic Lymphocy tic Leukemia. N Engl  J Med. 2016;374(4):323 -32.
Cai Q, H uang D, Yu H, Zhu Z, Xia Z, Su Y et al. COVID -19: Abnormal liver funct ion tests. J 
Hepatol. 2020.
CDC. COVID -19 Response Team. Severe outcomes among pat ients with coronavirus disease 
2019 (COVID -19) -[LOCATION_002], February 12 -March 16, 2020. MMWR. 2020;6 9:[ADDRESS_1283489] Microbe. 2016;19(2):[ADDRESS_1283490] ions: causes and 
consequences of cy tokine storm  and immunopathology . Semin Immunopathol . 
2017;39(5):[ADDRESS_1283491]. 2020.
Covey  T, Gul ranjani M, Cheung J, et al. Pharmacodynamic evaluat ion of acalabrut inib in 
relapsed/refractory  and treatment naive pat ients with chronic lymphocy tic leukemia (CLL) in 
the phase 1/2 A CE CL 001 study . Blood. 2017;130(Supplement 1):1741.
Florence JM, Krupa A, Booshehri LM, Davis SA, Matthay  MA , Kurdowska AK. Inhibit ing 
Bruton's t yrosine kinase rescues mice fro m lethal influenza -induced acute lung injury . Am J 
Physio l Lung Cell Mo l Physio l. 2018;315(1):L52 -L8.
Clinical Study Protocol -5.[ADDRESS_1283492]. Covariate -adjusted difference in proportions fro m clinical 
trials using logistic regression and weighted risk differences. Drug Inform J. 2011;45:481 -93.
Grasselli G, Zangrillo A, Zanella A, Antonelli M, Ca brini L, Castelli A et al. Baseline 
Characteristics and Outcomes of 1591 Patients Infected With SARS -CoV -2 Admitted to ICUs 
of the Lombardy  Regi on, Italy. JAMA. 2020.
Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX et al. Clinical Characteristics of 
Coronavir us Disease 2019 in China. N Engl J Med. 2020;382(18):1708 -20.
Herol d S, Becker C, Ri dge KM, Budinger GR. Influenza virus -induced lung injury : 
pathogenesis and implicat ions for treatm ent. Eur Respir J. 2015;45(5):1463 -78.
Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y et al. Clinical features of patients infected with 
2019 novel coronavirus in Wuhan, China. Lancet. 2020;395([ZIP_CODE]):497 -506.
Huang KJ, Su IJ, Theron M, Wu YC, Lai SK, Liu CC et al. An interferon -gamma -related 
cytokine storm  in SARS patients. J Med V irol. 2005;75(2):185 -94.
Li G, Fan Y, Lai  Y, Han T, Li  Z, Zhou P et al . Coronavirus infections and immune responses. 
J Med Viro l. 2020;92(4):[ADDRESS_1283493] ion. JCI Insight. 
2019;4(4).
Moine P, McInty re R, Schwartz MD, Kaneko D, Shenkar R, Le Tulzo Y et al. NF -kappaB 
regul atory  mechanisms in alveo lar macrophages from patients with acute respi[INVESTIGATOR_390933]. Shock. 2000;13(2):85 -91.
O'Riordan CE, Purvis GSD, Collotta D, Chiazza F, Wissuwa B, Al Zoubi S et al. Bruton's 
Tyrosine Kinase Inhibit ion Attenuates the Cardiac Dysfunct ion Caused by [CONTACT_913393]. Front iers in immuno logy. 2019;102129.
Page TH, Urbaniak AM, Espi[INVESTIGATOR_913349], Danks L, Smallie T, Williams LM et al. Bruton's 
tyrosine kinase regulates TLR7/8 -induced TNF transcript ion via nuclear factor -kappaB 
recrui tment. Bi ochem  Biophys Res Commun. 2018;499(2):[ADDRESS_1283494] disso lution to derive a P -PSD for PBPK model input. Eur J Pharm Biopharm. 
2019; 142:[ADDRESS_1283495] pulmo nary injury  in COVID -19 infected patients. 
Blood. 2020.
Wong CK, Lam CW, Wu AK, Ip WK, Lee NL, Chan IH et al. Plasma inflammatory  cytokines 
and chemokines in severe acute respi[INVESTIGATOR_7497]. Clin Exp Immunol. 2004;136(1):[ADDRESS_1283496] ics of and Important Lessons Fro m the Coronavirus 
Disease 2019 (CO VID-19) Outbreak in China: Summary  of a Report of [ADDRESS_1283497]. Severe acute respi[INVESTIGATOR_82326] e (SARS) 
coronavirus -induced lung epit helial cytokines exacerbate SARS pathogenesis by  [CONTACT_913394]-derived macrophages and dendrit ic cells. J Viro l. 
2009;83(7):3039 -48.
Zhao J, Zhao J, Van Rooijen N, Perlman S. Evasio n by [CONTACT_913395]: inefficient immune activat ion 
underlies poor T cell response and severe disease in SARS -CoV -infected mice. PLoS Pathog. 
2009;5(10):e1000636.
Zhao J, Li K, Wohlford -Lenane C, Agnihothram SS, Fett C, Zhao J et al. Rapid generation of 
a mouse m odel for Mi ddle East respi [INVESTIGATOR_7497]. Pr oceedings o f the Nati onal Academy  
of Sciences of the [LOCATION_002] of America. 2014;111(13):4970 -5.
Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z et al. Clinical course and risk factors for mortalit y 
of adul t inpatients wi th COVID -19 in Wuhan, China: a retrospec tive cohort study . Lancet. 
2020;395([ZIP_CODE]):1054 -62.
Clinical Study Protocol -5.0 [COMPANY_008]
Acalabrutinib -D822FC00003
CONFIDENTIAL AND PROPRIETARY 70of 103Appendix A Regulatory, Ethical and Study Oversight Considerations
A1 Regulatory and Ethical Considerations
This study  will be conducted in accordance wit h the protocol and with the fo llowing:
Consensus ethical prin ciples derived from international guidelines including the 
Declaration of Helsinki and Council for International Organizat ions of Medical Sciences 
(CIOMS) International Ethical Guidelines
Applicable Internat ional Council for Harmonisation (ICH) GCP Guideli nes
Applicable laws and regulations
The protocol, protocol amendments, ICF, Investigator ’sBrochure, and other relevant 
docum ents (eg, adverti sements) m ust be submitted to an IRB/IEC by  [CONTACT_24342] , and 
reviewed and approved by [CONTACT_1201]/IEC, before th e study  is init iated.  
Any amendments to the protocol will require IRB/IEC approval before implementation of 
changes made to the study  design, except for changes necessary  to eliminate an immediate 
hazard to study  subjects.  
The Investi gator will be resp onsible for the following:
Provi ding wri tten summaries of the status of the study  to the IRB/IEC annually  or m ore 
frequently in accordance with the requirements, policies, and procedures established by 
[CONTACT_1201]/IEC
Notifying the IRB/IEC of SAEs or other sig nificant safet y findings as required by 
[CONTACT_1744]/IEC procedures
Provi ding oversight of the conduct of the study  at the site and adherence to requirements 
of 21CFR, ICH guidelines, the IRB/IEC, European regulat ion536/2014 for clinical 
studi es (if applicable), and all other applicable local regulat ions
The study  will be perform ed in accordance with the Sponsor policy on Bioethics and Human 
Biological Samples.
A2 Financial Disclosure
Invest igators and sub -invest igators will provide the Sponsor with sufficient, accu rate financial 
inform ation as requested to allow the Sponsor to submit complete and accurate financial 
certification or disclosure statements to the appropriate regulatory  authori ties.  Invest igators 
are responsible for providing information on financial i nterests during the course of the study  
and for 1 year after completion o f the study .
Clinical Study Protocol -5.0 [COMPANY_008]
Acalabrutinib -D822FC00003
CONFIDENTIAL AND PROPRIETARY 71of 103A3 Informed Consent Process
The Investi gator or his/her representative will explain the nature of the study  to the subject or 
his/her legally  authori sed representative and answer all quest ions regarding the study .  
Subjects m ust be informed that their participation is voluntary . Subj ects or thei r legally  
authori sed representative will be required to sign a statement of informed consent that meets 
the requirements of 21CFR 50, local regul ations, ICH guidelines, Health Insurance Portabilit y 
and Accountabilit y Act(HIPAA) requi rements, where applicable, and the IRB/IEC or study  
center.  
The m edical  record m ust include a statem ent that wri tten inform ed consent was obtained 
before the subject was enro lled in the study  and the date and time the written consent was 
obtained. T he authorised person obtaining the informed consent must also sign the ICF.
Subjects m ust be re -consented to the most current versio n of the ICF(s) during their 
participat ion in the study.  
A copy  of the ICF(s) m ust be provi ded to the subject or the subje ct’s legally  authori zed 
representative.
Subjects will be told that they  are free to refuse to participate and may wit hdraw their consent 
at any  time and for any  reason during the sample storage period. If a subject withdraws 
consent to the use of donated b iological samples, the samples will be disposed of/destroyed, 
and the action documented. If samples already  have been analysed at the time of the request, 
the Sponsor will not be obliged to destroy  the results of thi s research.
A4 Data Protection
Each subject will be assigned a unique ident ifier by [CONTACT_1034] . Any subject records or data 
sets transferred to the Sponsor will contain only the ident ifier; subject names or any  
inform ation which would make the subject ident ifiable will not be transferred.  
The su bject must be informed that his/her personal study -related data will be used by  [CONTACT_19490]. The level o f disclosure m ust also be 
explained to the subject.  
The subject must be informed that his/her medical rec ords m ay be examined by  [CONTACT_73005] y Assurance auditors or other authorised personnel appo inted by  [CONTACT_1034] , by 
[CONTACT_6667]/IEC members, and by [CONTACT_32857].
Clinical Study Protocol -5.0 [COMPANY_008]
Acalabrutinib -D822FC00003
CONFIDENTIAL AND PROPRIETARY 72of 103A5 Committee Structures
An iDMC will be formed. Detailed informa tion regarding the composit ion of the iDMC and 
detailed iDMC procedures will be provided in a separate charter. The iDMC will be 
responsible for reviewing the safet y data periodically and provi de recommendat ions according 
to the charter.
The safet y of all Sponsor clinical studies is closely monitored on an ongo ing basis by [CONTACT_913396] y. Issues ident ified will be addressed; for 
example, this could invo lve amendments to the CSP and letters to Invest igator s.
A6 Disse mination of Clinical Study Data
A descript ion of this clinical trial will be available on http://astrazenecaclinicaltrials.co m and 
http://www.clinicaltrials.gov as will the summary  of the m ain study  resul ts when they  are 
available. The clinical trial and/o r summary  of main study  resul ts may also be available on 
other websites according to the regulat ions of the countries in which the main study  is 
conducted.
A7 Data Quality Assurance
All subject data relat ing to the study  will be recorded on printed CRF or eCR F unless 
transmitted to the Sponsor or designee electronically (eg, laboratory  data). The Investigator is 
responsible for verifying that data entries are accurate and correct by  [CONTACT_73007]/eCRF.
The Investi gator must maintain accurate docum entati on (source data) that supports the 
inform ation entered in the CRF/eCRF.
The Investi gator must permit study -related m onitoring, audi ts, IRB/IEC review, and 
regul atory  agency inspecti ons and provi de di rect access to source data docume nts.
The Sponsor or designee is responsible for the data management of this study  including 
qualit y checking of the data.
Study  monitors will perform  ongoing source data review to confirm  that data entered into the 
CRF/eCRF by  [CONTACT_913397], complete, and verifiable fro m source 
docum ents; that the safet y and ri ghts of  subjects are being protected; and that the study  is 
being conducted in accordance with the current ly approved protocol and any other study 
agreem ents, ICH GCP, and all applicable regulatory  requirements.
Records and documents, including signed ICFs, pertaining to the conduct of this study  must 
be retained by [CONTACT_210093] 15years after study co mpletion unless local regulat ions or 
institutional policies requi re alonger retention period. No records may be destroy ed during the 
Clinical Study Protocol -5.[ADDRESS_1283498] igator ’s site.
Data reported on the CRF/eCRF that are transcribed fro m source documents must be 
consis tent wi th the source documents or the discrepancies must be explained. The Investi gator
may need to request previous medical records or transfer records, depending on the study . 
Also, current medical records must be available.
Definit ions of what const itutes source data can be found in the Clinical Study  Agreement.
A9 Study and Site Closure
The Sponsor designee reserves the right to close the study site or terminate the study at any 
time for any  reason at the sole discret ion of the Sponsor . The study  may be stopped if, in the 
judgment of the Sponsor , trial subjects are placed at undue risk because of clinically 
significant findings that:
Meet individual stoppi[INVESTIGATOR_103414] 
Are assessed as causally rela ted to study  treatm ent, 
Are not considered to be consistent with cont inuat ion of the study
Regardless of the reason for terminat ion, all data available for the subject at the time of 
discontinuat ion of fo llow-up m ust be recorded in the CRF/eCRF. All reas ons for 
discontinuat ion of treatm ent m ust be docum ented.
In terminat ing the study, the Sponsor will ensure that adequate considerat ion is given to the 
protecti on of  the subjects’ interests.
Study  sites will be cl osed upon study  com pletion. A study  site is considered closed when all 
requi red docum ents and study  supplies have been collected and a study -site closure visit has 
been performed.
The Investi gator may initiate study -site closure at any time, provided there is reasonable cause 
and sufficient notice i s given in advance of the intended terminat ion.
Clinical Study Protocol -5.[ADDRESS_1283499] igator may include but 
are not limit ed to:
Failure of the Invest igator to com ply wit h the protocol, the requirements of the IRB/IEC 
or local health authori ties, the Sponsor 's procedures, or GCP guidelines
Inadequate recruit ment of subjects by  [CONTACT_24342]
Discontinuati on of  further study  treatm ent devel opment
A10 Publication Policy
The results of this study  may be published or presented at scientific meet ings once the primary 
analysis is completed and the study  is unblinded. No other publicat ions prior to that timepo int 
is allowed.
The Sponsor will co mply with the requi rements for publicat ion of study  resul ts. In accordance 
with standard edi torial and ethical pract ice, the Sponsor will generally support publicat ion of 
multicenter studies only in their entiret y and not as individual site data.  In this case, a 
coordinat ing Invest igator will be designated by [CONTACT_11402].
Authorship will be determined by  [CONTACT_73008] h Internat ional Committee 
of Medical Journal Editors authorship requirements.
Subsequent to the primary publicat ion, if an Investigator plans to publish any subset of data, 
or case report, the Invest igator agrees to submit all manuscripts or abstracts to the Sponsor 
before submissio n. This allows the Sponsor to protect proprietary  information and to provide 
comments .
Clinical Study Protocol -5.[ADDRESS_1283500] medical occurrence (other than progression of the 
disease under eval uation) in a pat ient or clinical study  subject administered a medicinal 
product and which does not necessarily have a causal relat ionship with this treat ment. An AE 
can therefore be any  unfavourable and unintended sign (eg, an abnormal laboratory  finding), 
symptom  (eg, nausea, chest pain), or disease temporally  associ ated wi th the use of a m edicinal 
product, whether or not considered related to the medicin al product.  
The term  AE is used to include both serious and non -serious AEs and can include a 
deteri oration of  a pre -exist ing medical occurrence. An AE may  occur at any  time, including 
run-in or washout periods, even if no study  treatm ent has been admini stered.
B2 Definition of Serious Adverse Events
A SAE is an AE occurring during any study  phase (i e, run -in, treatment, washout, fo llow-up), 
that fulfils one or more of the fo llowing cri teria:
Results in death
Is immediately life -threatening
Requi res in -patient hospi [INVESTIGATOR_24508] 
Results in persistent or significant disabilit y or incapaci ty
Is a congenital abnormalit y or birth defect
Is an important medical event that may jeopardize the subject or may require medi cal 
treatm ent to prevent one of the outcomes listed above.
B3 Life-threatening
‘Life -threatening’ means that the subject was at immediate risk of death from the AE as it 
occurred, or it is suspected that use or continued use of the product would result in th e 
subject’s death. ‘Life -threatening’ does notmean that, had an AE occurred in a more severe 
form, it might have caused death (eg, hepat itis that resolved without hepatic failure).
B4 Hospi[INVESTIGATOR_96698] a seri ous AE, al though the reasons 
for it may be (eg, bronchospasm, laryngeal oedema). Hospi[INVESTIGATOR_2144]/or surgical 
operati ons planned before or during a study  are not consi dered AEs if the illness or disease 
existed before the subject was enrolled in the study, provided that it did not deteriorate in an 
unexpected way  during the study .
Clinical Study Protocol -5.[ADDRESS_1283501] drug does not mean that it is an important medical event; medical 
judgement must be used.
Angioedema not severe enough to require intubation but requiring intravenous 
hydrocortisone trea tment
Hepatotoxicit y caused by [CONTACT_33153] l (acetaminophen) overdose requiring treatment with 
N-acetylcysteine
Intensive treatment in an emergency room or at home for allergic bronchospasm
Blood dy scrasias (eg, neutropenia or anemia requiring blood transfus ion, etc.) or 
convulsio ns that do not result in hospi[INVESTIGATOR_18543]
Development of drug dependency or drug abuse
B6 Intensity Rating Scale
The grading scales found in the revised NCI CTCAE v5.0 will  be utilized for all events with 
an assigned CTCAE grading. For those events wi thout assigned CTCAE grades, the 
recommendat ion in the CTCAE criteria that converts mild, moderate and severe events into 
CTCAE grades should be used. A copy  of the CTCAE can be downloaded from the Cancer 
Therapy  Evaluat ion Program website 
(https://ctep.cancer.gov/protocolDevelopment/electronic_applicat ions/docs/CTCAE_v5_Quic
k_Reference_8.5x11.pdf ).
It is important to dist inguish between serious and severe AEs. Severit y is a measure of 
intensity whereas seri ousness is defined by [CONTACT_73010] B2. An AE of severe 
intensity need not necessarily be considered serious. For example, nausea that persists for 
several hours may  be cons idered severe nausea, but not a SAE unless it meets the criteria 
shown in Appendix B2. On the other hand, a stroke that results in only a limited de gree of 
disabili ty may be considered a mild stroke but would be a SAE when it satisfies the criteria 
shown in Appendix B2.
Clinical Study Protocol -5.0 [COMPANY_008]
Acalabrutinib -D822FC00003
CONFIDENTIAL AND PROPRIETARY 77of 103B7 A Guide to Interpreting the Causality Question
When assessing causalit y consider the fo llowing factors when deciding if there is a 
‘reasonable possibilit y’ that an AE may  have been caused by  [CONTACT_33641].
Time Course. Exposure to suspect drug. Has the subject actually rec eived the suspect 
drug?  Di d the AE occur i n a reasonable temporal relat ionship to the administration of the 
suspect drug?
Consistency wit h known drug profile. Was the AE consistent with the previous 
knowl edge of the suspect drug (pharmaco logy and toxi cology) or drugs of the same 
pharmaco logical class? Or could the AE be ant icipated from its pharmaco logical 
properties?
De-challenge experience. Did the AE resolve or improve on stoppi[INVESTIGATOR_122570]?
No al ternative cause. The AE ca nnot be reasonably explained by [CONTACT_73011], other drugs, other host or environmental factors.
Re-challenge experience. The Sponsor would not norm ally reco mmend or support a 
re-challenge.
Laboratory  tests. A specific la boratory  invest igation (if performed) has confirmed the 
relationship.
In difficult cases, other factors could be considered such as:
Is this a recognized feature of overdose of the drug?
Is there a known mechanism?
Causalit y of ‘related’ is m ade if fo llowing a review of the relevant data, there is evidence for a 
‘reasonable possibilit y’ of a causal relationship for the individual case. The expressio n 
‘reasonable possibilit y’ of a causal relationship is meant to convey, in general, that there are 
facts (ev idence) or arguments to suggest a causal relat ionship.
The causalit y assessment i s perform ed based on the available data including enough 
inform ation to m ake an informed judgment. With limited or insufficient informat ion in the 
case, i t is likely  that the event(s) will be assessed as ‘not related’.
Causal relat ionship in cases where the disease under study  has deteri orated due to l ack of 
effect shoul d be classified as no reasonable possibilit y.
B8 Medication Error
For the purposes of this clinical study  a medication error is an unintended failure or mistake in 
the treatment process for a Sponsor study treatment that either causes harm to the subject or 
has the potential to cause harm to the subject.  
Clinical Study Protocol -5.[ADDRESS_1283502].
Medicat ion error includes situat ions where an error:  
Occurred
Was i dentified and intercepted before the subject received the drug
Did not occur, bu t circumstances were recognized that could have led to an error
Examples of events to be reported in clinical studies as medication errors:
Drug name [CONTACT_33165] n
Dispensing error, eg, medicat ion prepared incorrectly, even if it was not actually given to 
thesubject
Drug not administered as indicated, for example, wrong route or wrong site of 
administration
Drug not taken as indicated, eg, tablet disso lved in water when it should be taken as a 
solid tablet 
Drug not stored as instructed, eg, kept in the fridg e when i t shoul d be at room  temperature 
Wrong subject received the medicat ion (excluding IRT errors)
Wrong drug administered to subject (excluding IRT errors)
Examples of events that do not require reporting as medicat ion errors in clinical studies:
Errors related to or resulting fro m IRT -including those which lead to one of the above 
listed events that would otherwise have been a medicat ion error 
Subject accidentally  missed drug dose(s), eg, forgot to take medicat ion
Accidental  overdose (will be captu red as an overdose)
Subject failed to return unused medicat ion or em pty packaging
Errors related to background and rescue medicat ion, or standard of care medicat ion in 
open l abel studi es, even if an A straZeneca product 
Medicat ion errors are not regarded as AEs, but AEs may occur as a consequence of the 
medicat ion error.
Clinical Study Protocol -5.0 [COMPANY_008]
Acalabrutinib -D822FC00003
CONFIDENTIAL AND PROPRIETARY 79of 103Appendix C Handling of Human Biological Samples
C1 Chain of Custody of Biological Samples
A full chain o f custody  is maintained for all samples throughout their lifecycle.
The Investi gator at each cente r keeps full traceability  of collected bi ological sam ples f rom the 
subjects while in storage at the centre until shipment or disposal (where appropriate).
The sample receiver keeps full traceabilit y of the sam ples while in storage and during use unt il 
used or disposed of or until further shipment and keeps documentation of receipt of arrival.
The Sponsor will keep oversight of the ent ire life cycle through internal procedures, 
monitoring of study  sites, audi ting or process checks, and contractual requirements of external 
laboratory  provi ders.
Samples retained for further use will be stored in the Sponsor -assigned bio banks and will be 
registered by  [CONTACT_913398]. 
If required, the Sponsor will ensure that remaining bio logical  samples are returned to the site 
according to local regulations or at the end of the retention period, whi chever i s the sooner.
C2 Withdrawal of Informed Consent for Donated Biological Samples
If a subject withdraws consent specifically  to the subsequent use of donated biological 
samples, the samples will be disposed of/destroy ed, and the acti on docum ented. If samples are 
already analyzed, the Sponsor is not obliged to destroy  the resul ts of this research. A general 
withdrawal  of consent to study  treatm ent does not imply  a wi thdrawal  of consent to 
subsequent analyses of bio logical samples. In case a subject withdraws the general informed 
consent and addit ionally  wants to wi thdraw consent for further analyses of his/her bio logical 
samples, the subject is required to sign an opt -out.
As collect ion of the bio logical sample(s) i s an integral  part of the stu dy, then the subject is 
withdrawn from  further study  parti cipat ion.
The Investi gator :
Ensures subjects’ wit hdrawal o f informed consent to the use of donated samples is 
notified immediately to Sponsor
Ensures that bio logical samples from that subject, if st ored at the study  site, are 
immediately  identified, disposed of /destroy ed, and the action documented
Ensures the organizat ion(s) ho lding the samples is/are informed about the withdrawn 
consent immediately and that samples are disposed of/destroy ed, the ac tion docum ented, 
and the signed document returned to the study  site
Clinical Study Protocol -5.0 [COMPANY_008]
Acalabrutinib -D822FC00003
CONFIDENTIAL AND PROPRIETARY 80of 103Ensures that the subject and Sponsor are informed about the sample disposal.
The Sponsor ensures the organization(s) ho lding the samples is/are informed about the 
withdrawn consent immedi ately and that sam ples are disposed of/destroy ed and the act ion 
docum ented and returned to the study  site.
C3 International Airline Transportation Association Regulations on 
Labeling and Shipment of Biological Samples
Air transportation of bio logical sam ples (including biohazardous materials and potentially  
biohazardous materials) is regulated under Internatio nal Airline Transportation Association 
(IATA) Dangerous Goods Regulat ions (DGR; 61st edition [2020]) Divisio n6.2—Infect ious 
Substances. The IATA DGR def inition of infect ious substances includes any  substance that is 
known or reasonably expected to contain pathogens, ie, microorganisms (including bacteria, 
viruses, rickettsiae, parasites, fungi) or other agent, such as a proteinaceous infect ious parti cle 
(prion), that can cause disease in humans or animals.
As Divisio n6.[ADDRESS_1283503] be cl assified 
as Category A, Category B, or Exem pt; secured in IATA -compliant packaging; and ident ified 
using the appropr iate United Nations shippi[INVESTIGATOR_913350], sample ty pe, and infect ious nature of material being shipped. See Table 7for 
details.
Under IATA regulat ions, subject specimens from clinical trials will fall into Category B or 
Exempt. Clinical trial samples can often be packed and transported at ambient temperature.  
However, in cases where bio logical samples m ust be refrige rated or frozen for transport (eg, 
using dry  ice or liquid nitrogen), addit ional dangerous goods specifications will apply; refer to 
DGR Section [IP_ADDRESS].3.8 (e). IATA -compliant couriers and materials should be used for 
transportation and packaging, and whe re applicable, packing should be done by 
[CONTACT_913399] -certified personnel. 
Transportation of bio logical  samples by  [CONTACT_913400] l ocal regul ations 
requi ring shipment in safe, appropriate packaging materials to contain any risk o f infect ion or 
contaminat ion at all times, in addit ion to the use of approved couriers. Wherever possible, 
compliance wi th IATA Instructi on650 standards for bio logical sample containment are 
encouraged for road or rail transport of subject specimens. 
Clinical Study Protocol -5.0 [COMPANY_008]
Acalabrutinib -D822FC00003
CONFIDENTIAL AND PROPRIETARY 81of 103Table 7 IATA Dangerous Goods Regulations Classification of Infectious 
Substances
CategoryaDescription Shippi[INVESTIGATOR_913351] A 
infectious 
substancesAny infectious substance 
transported in a form that, 
when exposure occurs,bis 
capable of causing permanent 
disability, life threatening 
disease, or fatal disease in 
otherwise healthy humans or 
animals.  
(Examples include Ebola and 
Lassa fever virus.)Category  A pathogens must 
be: 
Packed and shipped in 
accordance with IATA 
Instructio n620 
Identified using the 
appropriate UN shippi[INVESTIGATOR_913352] 2814
“Infectious substances 
affecting humans or both 
humans and animals”
UN 2900
“Infectious substances 
affecting animals only”
Category B 
infectious 
substancesAny infectious substance that 
does not meet the criteria for 
inclusion in Category A.  
Category  B infectious 
substances are not in a form 
capable of causing permanent 
disability, life threatening 
disease, or fatal disease in 
otherwise healthy humans or 
animals when exposure 
occurs.b
(Examples include hepatitis A, B, 
C, D, and E viruses, and HIV 
types 1 and 2.)Category  B pathogens must 
be: 
Packed and shipped in 
accordance with IATA 
Instructio n650 
Identifi ed using the 
appropriate UN shippi[INVESTIGATOR_913352] 3373 
“Biological substance, 
Category B”
Exempt 
substancesSubject specimens for which 
there is minimal likelihood 
that pathogens are present. 
(Examples may include 
blood -based samples, tissue 
cultures, or other biological 
samples.)Exempt substances must be: 
Packed and shipped in 
accordance with 
requirements specified in 
Division 6.2, 
Section [IP_ADDRESS].3.8 of the 
IATA DGRa
Identified using the 
appropriate label 
information“Exempt huma n specimen”
“Exempt animal specimen”
DGR = Dangerous Goods Regulation; IATA = International Airline Transportation Association; UN = United Nations.
Note:  IATA Dangerous Goods Regulations, 61st Edition. 01 January 2020. International Air Transport Association. 
Available at: https://www.iata.org/en/programs/cargo/dgr/download/.
aFor transport purposes, the classification of infectious substances according to risk groups was removed in the DGR 
46th edition (2005).  There is no direct relationship betwe en risk groups and Categories A and B.
bExposure occurs when an infectious substance is released outside of the protective packaging, resulting in physical 
contact [CONTACT_913401].
Clinical Study Protocol -5.0 [COMPANY_008]
Acalabrutinib -D822FC00003
CONFIDENTIAL AND PROPRIETARY 82of 103Appendix D Actions Required in Cases of Increases in Liver 
Biochemistry and Evaluation of Hy’s Law
D1 Introduction
This Appendix describes the process to be fo llowed in order to ident ify and appropriately 
report Potential Hy’s Law (PHL) cases and Hy’s Law (HL) cases.  It is not intended to be a 
comprehensive gui de to the m anagement of elevated liver biochemistries. 
During the course of the study  the Invest igator will remain vigilant for increases in liver 
biochemistry .  The Invest igator is responsible for determining whether a subject meets 
potenti al PHL cri teria at any  point duri ng the study.
All sources of l aboratory  data are appropri ate for the determinat ion of PHL and HL events; 
this includes samples taken at scheduled study  visits and other vi sitsincluding central and all 
local laboratory  evaluat ions even if co llected outside of the study  visit s; for exam ple, PHL 
criteria coul d be m et by  [CONTACT_96724]  a central  laboratory  and/or elevated TBL fro m 
a local laboratory . 
The Investigator will also review AEdata (for example, for AEs that may  indicate el evati ons 
in liver bio chemistry ) for possible PHL events.
The Investigator participates, together with [COMPANY_008] clinical project representatives, in 
review and assessment of cases meet ing PHL criteria to agree whether HL criteria are met.  
HL cri teria are m et if there is no alternat ive explanation for the elevat ions in liver 
biochemistry  other than Drug Induced Liver Injury (DILI) caused by  [CONTACT_309582] (IMP). 
The Inve stigator is responsible for recording data pertaining to PHL/HL cases and for 
reporting SAEs and AEs according to the outcome of the review and assessment in line wit h 
standard safet y reporting processes.
D2 Definitions
Potential Hy’s Law
AST or ALT ≥ 3x ULN together with Total Bilirubin (TBL) ≥ 2x ULN at any  point during 
the study  following the start of study  medicat ionirrespective of an increase in alkaline 
phosphatase (ALP).
Hy’s Law
AST or ALT ≥ 3x ULN together with TBL ≥ 2x ULN, where no other reason, o ther than the 
IMP, can be found to explain the combinat ion of increases, eg, elevated ALP indicating 
cholestasis, viral hepat itis, another drug.  
Clinical Study Protocol -5.[ADDRESS_1283504] precede or be coincident with (i.e. on the 
same day ) the e levation in TBL, but there is no specified timeframe within which the 
elevations in transaminases and TBL must occur.
D3 Identification of Potential Hy’s Law Cases
In order to i dentify  cases of PHL i t is important to perform a comprehensive review of 
laborato ry data for any  subject who m eets any of the fo llowing i dentificat ion criteria in 
isolation or in combinat ion:
ALT ≥ 3xULN
AST ≥ 3xULN
TBL ≥ 2xULN
Central laboratories being used:
When a subject meets any o f the PHL i dentificat ion criteria, in isol ation or in co mbinat ion, the 
central  laboratory  will immediately  send an alert to the Invest igator (also sent to [COMPANY_008] 
representative). 
The Investigator will also remain vigilant for any  local  laboratory  reports where the PHL 
ident ificat ion criteria are me t, where thi s is the case the Investigator will:
Notify  the [COMPANY_008] representative 
Request a repeat of the test (new blood draw) by  [CONTACT_122647]
Com plete the appropri ate unscheduled laboratory  CRF m odule(s) wi th the ori ginal  local 
laboratory  test resul t
When the identificat ion criteria are m et from central  or local laboratory  resul ts the Invest igator 
will wit hout del ay:
Determine whether the subject meets PHL criteria (see Section D2within this Appendix 
for definit ion) by [CONTACT_309583] (including both 
central  and l ocal laboratory  resul ts)
Local laboratories being used:
The Investig ator will wi thout del ay review each new laboratory  report and if the ident ificat ion 
criteria are met will:
Notify  the [COMPANY_008] representative 
Determine whether the subject meets PHL criteria ( see Section D2within this Appendix 
for definit ion) by [CONTACT_42574] l aboratory  reports from all previous visits
Clinical Study Protocol -5.0 [COMPANY_008]
Acalabrutinib -D822FC00003
CONFIDENTIAL AND PROPRIETARY 84of 103Prom ptly enter the laboratory  data into the l aboratory  CRF
D4 Follow -up
D4.1 Potential Hy’s Law Criteria not met
If the sub ject does not meet PHL criteria the Investigator will:
Inform  the [COMPANY_008] representative that the subject has not met PHL criteria.
Perform  follow-up on subsequent laboratory  resul ts according to the guidance provided in 
the Clinical Study  Protocol .
D4.2 Potential Hy’s Law Criteria met
If the subject does meet PHL criteria the Invest igator will:
Determine whether PHL criteria were met at any  study  visit prior to starting study  
treatm ent
Notify  the [COMPANY_008] representative who will then inform the central Study  Team  
Within [ADDRESS_1283505] igator will report the case as an SAE of 
Potenti al Hy’s Law; seri ous cri teria ‘Im portant m edical event’ and causalit y assessment 
‘yes/related’ according to CSP process for SAE reporting.
For sub jects that m et PHL cri teria prior to starti ng IMP, the invest igator is not required to 
submit a PHL SAE unless there is a significant change #in the subject’s condit ion
The Study  Physician contacts the Invest igator, to provide guidance, discuss and agree a n 
approach for the study  subjects’ foll ow-up (including any  further l aboratory  testing) and 
the continuous review o f data
Subsequent to this contact [CONTACT_73016]:
Moni tor the subject until liver biochemistry  parameters and appropriate clinical 
symptoms and signs return to normal or baseline levels, or as long as medically 
indicated. Completes fo llow-up SAE Form as required.
Invest igate the aetiology o f the event and perform diagnostic investigat ions as 
discussed wi th the Study  Physician. This in cludes deci ding which the tests available 
in the Hy’s law lab kit should be used 
Com plete the three Liver CRF Modules as information becomes available 
# A ‘significant’ change in the subject’s condit ion refers to a clinically relevant change in 
any of t he individual liver biochemistry  param eters (ALT, AST or total bilirubin) in 
isolation or in combinat ion, or a clinically  relevant change in associated symptoms.  The 
determinat ion of whether there has been a significant change will be at the discret ion of
the Invest igator ;this may  be in consul tation wi th the Study  Physician if there is any 
uncertaint y.
Clinical Study Protocol -5.0 [COMPANY_008]
Acalabrutinib -D822FC00003
CONFIDENTIAL AND PROPRIETARY 85of 103D5 Review and Assessment of Potential Hy’s Law Cases
The instructions in this section shoul d be fo llowed for all  cases where PHL cri teria are m et.
As soon as possible after the biochemistry abnormalit y was ini tially detected, the Study  
Physician contacts the Invest igator in order to review available data and agree on whether 
there is an alternat ive explanat ion for meeting PHL criteria other than DILI caused by [CONTACT_86184], to ensure timely analysis and reporting to healt h authorit ies wit hin [ADDRESS_1283506] and TBL elevations, 
a determina tion of  whether the al ternat ive explanatio n is an AE will be made and 
subsequent ly whether the AE meets the criteria for a SAE:
If the alternat ive explanat ion is notan AE, record the alternative explanation on the 
appropriate CRF
If the alternat ive explanat ion is an AE/SAE: update the previously submitted Potential 
Hy’s Law SAE and AE CRFs accordingly wit h the new information (reassessing event 
term; causalit y and seri ousness cri teria) fo llowing the AZ standard processes.
If it is agreed that there is no explanat ion that would explain the ALT or AST and TBL 
elevations other than the IMP:
Send updated SAE (report term ‘Hy’s Law’) according to [COMPANY_008] standard 
processes. 
 The ‘Medically  Important’ seri ous cri terion shoul d be used if no other seriou s 
criteria apply
 As there is no alternat ive explanation for the HL case, a causalit y assessment of 
‘related’ should be assigned.
If, there i s an unavo idable delay, of over 15 calendar day s in obtaining the informat ion 
necessary  to assess whether or not th e case meets the criteria for HL, then it is assumed that 
there is no alternat ive explanation unt il such time as an informed decisio n can be made:
Provi des any  further update to the previously submitted SAE of Potential Hy’s Law, 
(report term now ‘Hy’s Law case’) ensuring causalit y assessment i s related to IMP and 
seriousness cri teria is m edically important, according to Clinical Study Protocol ( CSP)
process for SAE reporting.
Clinical Study Protocol -5.0 [COMPANY_008]
Acalabrutinib -D822FC00003
CONFIDENTIAL AND PROPRIETARY 86of 103Continue fo llow-up and review according to agreed plan.  Once the necessary  
supplementary  informat ion is obtained, repeat the review and assessment to determine 
whether HL criteria are still met.  Update the previously submitted PHL SAE report 
following CSP process for SAE reporting, according to the outcome of the review and 
amending the reported term if an alternat ive explanat ion for the liver biochemistry  
elevations is determined.
D6 Laboratory tests
Hy’s Law Laboratory Kit for Central Laboratories
Additional standard chemistry and coagulation 
testsGGT
LDH
Prothrombin time
INR
Viral hepatitis IgM anti -HAV 
IgM and IgG anti -HBc
HBsAg
HBV DNA
IgG anti -HCV
HCV RNA* 
IgM anti -HEV
HEV RNA
Other viral infections IgM & IgG anti -CMV
IgM & IgG anti -HSV
IgM & IgG anti -EBV
Alcoholic hepatitis Carbohydrate deficient transferrin ( CD-
transferrin)**
Autoimmune hepatitis Antinuclear antibody (ANA)
Anti-Liver/Kidney Microsomal Ab (Anti -LKM)
Anti-Smooth Muscle Ab (ASMA)
Metabolic diseases alpha -1-antitrypsin
Ceruloplasmin
Iron
Ferritin
Transferrin
Transferrin saturation
*HCV RNA is only tested when IgG anti -HCV is positive or inconclusive
**Carboh ydrate deficient transferrin ( CD-transferrin) is not available in China. Study teams should amend this 
list accordingly
Reference
Aithal et al 2011, Clinical Pharmaco logy and Therapeuti cs 89(6):806 -815. 
http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatory Information/Guidances
/UCM174090.pdf .
Clinical Study Protocol -5.[ADDRESS_1283507] 
shoul d be addressed to the Medi cal Moni torof this study .
Table 8 CYP3A Inhibitors
Strong inhibitors of CYP3 A Moderate inhibitors of CYP3A
Boceprevir aprepi[INVESTIGATOR_913353],bverapamila
Nefazodone
nelfinavira
paritaprevir and ritonavir and (ombitasvir and/or dasabuvir)b
Posaconazole
ritonavira,b
saquinavir and ritonavira,b
telaprevira
tipranavir and ritonavira,b
Troleandomycin
Voriconazole
aInhibitor of P -glycoprotein.
bRitonavir is usually given in combination with other anti -HIV or anti-HCV drugs in clinical practice. Caution should 
be used when extrapolating the observed effect of ritonavir alone to the effect of combination regimens on CYP3A 
activities.
Clinical Study Protocol -5.[ADDRESS_1283508]. Jo hn’s worta
aThe effect of St. John’s wort varies widely and is preparation -dependent.
Source: US FDA. Drug development and drug interactions: table of substrates, inhibitors and inducers. 
http://www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/DrugInteractionsLabeling/ucm093664.h
tm#inVivo. Accessed 23 July 2019.
Table 10 Other Drugs Needing Additional Considerations
Proton pump inhibitors H2-receptor antagonists
Dexlansoprazole cimetidine
Esomeprazole famotidine
Lansoprazole nizatidine
Omeprazole
Rabeprazole
Pantoprazole
Source: US FDA. Established pharmacologic class text phrase. https://www.fda.gov/downloads/drugs/
guidancecomplianceregulatoryinformation/lawsactsandrules/ucm428333. pdf. Accessed [ADDRESS_1283509] -menarche, not 
surgi cally sterile (i e, bilateral  salpi[INVESTIGATOR_1656] , bilateral  oophorectomy, or com plete 
hysterect omy) or post -menopausal.
Women will  be considered post -menopausal if they have been amenorrheic for 12 months 
without an al ternat ive medical cause.  The following age -specific requirements apply:
Women <[ADDRESS_1283510] itution.
Women ≥50years of age woul d be considered post -menopausal if they have been 
amenorrheic for [ADDRESS_1283511] menses >[ADDRESS_1283512] men ses >[ADDRESS_1283513] inent (ie, refraining 
from heterosexual intercourse during the ent ire period of risk associated with study  
treatm ents), and who intend to be sexually act ive with anonsterilized male partner, must use 
at least one highly effect ive method of contraception (see Table 11) consistent with local 
regul ations regarding the use of contraception for subjects participat ing in clinical trials, from 
the time o f signing the ICF throughout the total duration of the drug treatm ent and the drug 
washout period ([ADDRESS_1283514] dose of acalabruti nib). 
Non-sterilized male partners of a female subject of childbearing potential must use a male 
condom  plus spermicide (condom  alone in countries where spermicides are not approved) 
throughout this period. Cessat ion of birth control after this point should be discussed with a 
responsible physician. Periodic a bstinence, the rhythm method, and the withdrawal method 
are not acceptable methods of contraception. The reliabilit y of total  sexual  abstinence shoul d 
be evaluated in relat ion to the duration of the clinical trial and the preferred and usual lifest yle 
of the subject . Fem ale subjects shoul d refrain fro m breast feeding throughout this period.  
F2 Male Subjects with a Female Partner of Childbearing Potential
Non-sterilized male subjects (including males sterilized by  a method other than bilateral 
orchi dectomy , eg, vasectomy ) who are not abst inent and intend to be sexually act ive with a 
female partner of childbearing potential must use a male condom plus spermicide (condom 
alone in countri es where spermicides are not approved) from the time of screening throughout 
Clinical Study Protocol -5.0 [COMPANY_008]
Acalabrutinib -D822FC00003
CONFIDENTIAL AND PROPRIETARY 90of 103the total durat ion of the drug treatment and the drug washout period ([ADDRESS_1283515] dose 
of acalabrutinib ).Periodic abst inence, the rhy thm method, and the withdrawal method are not 
acceptable methods of contraception. Male subjects shoul d refrain from sperm  donat ion 
throughout this period.
Vasectomized (ie, sterile) males are considered fertile and should st ill use a male condo m plus 
spermicide as indicated above during the clinical trial.
Even if the female partner is pregnant, male subjects shoul d still use a condom, as indicated 
above during the clinical trial, if there is a concern about damaging the developi[INVESTIGATOR_913354].
Female partners (of childbearing potential) of male subjects must also use a highly effect ive 
method of co ntracepti on throughout this period (see Table 11).
F3 Highly Effective Methods of Contraception
Highly effect ive methods of contraception, defined as one that results in a low failure rate 
(ie,less than 1% per year) when used consistent ly and correctly, are described in Table 11. 
Note that som e contraception methods are not considered highly effective (eg, male or female 
condom  with or wi thout spermici de; female cap, diaphragm, or sponge with or without 
spermicide; no n copper containing intrauterine device; progestogen -only oral horm onal 
contraceptive pi[INVESTIGATOR_285944] [excluding 
Cerazette/desogestrel which is considered highly effective]; and triphasic co mbined oral 
contraceptive pi[INVESTIGATOR_3353]).
Table 11 Highly Effective Methods of Contraception (<1% Failure Rate)
Barrier/intrauterine methods Hormonal methods
• Copper T intrauterine device
• Levonorgestrel -releasing intrauterine system 
(eg, Mirena®)a• Implants: Etonogestrel -releasing implants 
(eg,Implanon®or Norplant®)
• Intravaginal devices: 
Ethinylestradiol/etonogestrel -releasing 
intravaginal devices (eg, NuvaRing®) 
• Injection: Medroxyprogesterone injection 
(eg,Depo -Provera®)
• Combined pi[INVESTIGATOR_4382]: Normal an d low dose combined 
oral contraceptive pi[INVESTIGATOR_4382]
• Patch: No relgestromin/ethinylestradiol -releasing 
transdermal system (eg, Ortho Evra®)
• Minipi[INVESTIGATOR_4382]: Progesterone based oral contraceptive 
pi[INVESTIGATOR_72908]: Cerazette®is currently the 
only highly  effective progesterone -based pi[INVESTIGATOR_285945] a hormonal method.
Clinical Study Protocol -5.0 [COMPANY_008]
Acalabrutinib -D822FC00003
CONFIDENTIAL AND PROPRIETARY 91of 103Appendix G Child-Pugh Score
Cirrhosi s severi ty, as determined by  [CONTACT_128769] -Pugh score ( Pugh 1973 ), will be recorded in the 
eCRF as specified in the SoAs.
The m odified Child -Pugh classificat ion of liver disease severit y according to the degree of 
ascites by  [CONTACT_461], serum  concentrati ons of bilirubin and albumin, prothrombin time, 
and degree of encephalopathy is shown in Table 12. The severit y of cirrhosis is classified as 
follows:
Child -Pugh cl ass A (well -compensated disease): score of 5 to 6
Child -Pugh cl ass B (significant functional compromise): score of 7 to 9
Child -Pugh cl ass C (decom pensated di sease): score of 10 to 15
Table 12 Child -Pugh Classification of Cirrhosis Severity
Parameter Points assigned
1 2 3
Ascites Absent Slight Moderate
Bilirubin <2 mg/dL
(<34.2 μmol/L)2 to 3 mg/dL
(34.2 to 51.3 μmol/L)>3 mg/dL
(>51.3 μmol/L)
Albumin >3.5 g/dL
(35 g/L)2.8 to 3.5 g/dL
(28 to 35 g/L)<2.8 g/dL
(28 g/L)
Prothrombin time
Seconds over control <4 4 to 6 >6
INR <1.7 1.7 to 2.3 >2.3
Encephalopathy None Grade 1 to 2 Grade 3 to 4
INR =international normalized ratio.
Clinical Study Protocol -5.[ADDRESS_1283516] supportive care
Btk Bruton’s ty rosine kinase
BUN Blood urea ni trogen
CBC Com plete bl ood count
CI Confidence interval
Cmax Maximum observed concentration
COVID -19 Coronavirus disease 2019
CRF Case report form (electronic/paper)
CRP C-reactive protein
CSP Clinical Study  Protocol
CT Com puted tom ography
CTCAE Commo n Termino logy Criteria f or Adverse Events
CYP Cytochrom e P450
DGR Dangerous Good Regulat ion
DILI Drug -induced liver injury
DLT Dose -limit ing toxicit y
ECG Electrocardiogram
eCRF Electronic case report form
eGFR Estimated glo merular filtration rate
FiO2 Fract ion of inspi[INVESTIGATOR_913355] B surface ant igen
HBV Hepati tis B vi rus
HCV Hepati tis C vi rus
HL Hy’s law
Clinical Study Protocol -5.[ADDRESS_1283517] ionary for Regulatory  Activities
MRI Magnet ic resonance imaging
NCI National Cancer Institute
NG Nasogastri c
NYHA [LOCATION_001] Heart Associat ion
PaCO 2 Parti al pressure of carbon dio xide
PaO2 Parti al pressure of oxy gen
PCR Polymerase chain reaction
PD Pharmacodynamic(s)
PD-1 Programmed cell death 1
PHL Potenti al Hy’s law
PI3K Phosphat idylinosito l-3-kinase
PK Pharmacokinet ic(s)
PML Progressive mult ifocal leukoencephalopathy
PPI [INVESTIGATOR_238553] -pump inhibitor
PT Prothrombin t ime
qd Once daily
SAE Serious adverse event
SAP Statistical Analysis Plan
SARS -CoV -[ADDRESS_1283518] Upper limit of normal
Clinical Study Protocol -5.0 [COMPANY_008]
Acalabrutinib -D822FC00003
CONFIDENTIAL AND PROPRIETARY 95of 103Appendix I Protocol Amendment History
The Protocol Amendment Summary of Changes Table for the current amendment is located 
directly before the Table of Contents.
Amendment 3 (23Jun2020) 
The overall rationale for th e amendment was to address feedback from study  sites that are 
managing local challenges during the COVID -19 pandemic.
Section number and 
nameDescription of change Brief rationaleSubstantial/ 
non-substantial
1.1 Schedule of 
Activities (Table 1)Added footnote l to indicate that 
screening can be performed within 
1-3 days prior to dosingAllow flexibility around 
timing of screening Non-substantial
Added footnote o to indicate that 
 
 
 Clarification Non-substantial
Added footnote q to indicate that for 
all central laboratory assessments, 
sample collection windows of ± 1 
day will be allowed for each of 
Days 3 and 7.Clarification Non-substantial
Added a separate column for Day 1 Clarification Non-substantial
Specified in title that Table 1 only 
applies to Arm 1 (acalabrutinib + 
BSC)Clarification Non-substantial
1.1 Schedule of 
Activities (Table 2)Added Table 2 for Arm 2 (BSC 
only) assessmentsClarification Non-substantial
1.1 Schedule of 
Activities (Table 1);
6.1 Treatments 
AdministeredRevised the statement 
“Acalabrutinib must be 
administered within 6 hours of 
randomization” to “Acalabrutinib 
should be administered within 6 
hours of randomization”Patient centricity Non-substantial
CCI
Clinical Study Protocol -5.0 [COMPANY_008]
Acalabrutinib -D822FC00003
CONFIDENTIAL AND PROPRIETARY 96of 103Section number and 
nameDescription of change Brief rationaleSubstantial/ 
non-substantial
1.1 Schedule of 
Activities (Table 1);
8.1.[ADDRESS_1283519], or any other 
appropriate means to confirm 
pneumonia prior to or upon 
hospi[INVESTIGATOR_059] (within 7 days of 
randomization).Clarification Non-substa ntial
1.1 Schedule of 
Activities (Table 1);
8.1.[ADDRESS_1283520] dose of study drug 
should be used.Clarification Non-substantial
1.1 Schedule of 
Activities (Table 1);
8.1.8 Laboratory TestsRevised footnote d in Table 1 and 
text in Section 8.1.8 to indicate that 
hepatitis serology should include, at 
a minimum, HBsAg, anti -HBc, and 
HCV antibody. Also, stated that if 
additional hepatitis serology is 
collected per institutional 
guidelines, it should be recorded in 
the database.Clarification Non-substantial
1.1 Schedule of 
Activities (Table 1);
8.1.8 Laboratory Tests;
8.3 On -study 
ProceduresRevised Table 1 and Sections 8.1.8 
and 8.3 so that collection of ferritin, 
D-dimer, fibrinogen, PT, aPTT, 
INR, and procalcitonin to occur 
every other day while i n the 
hospi[INVESTIGATOR_307], and cardiac troponin I to 
be collected on Day 5 while in the 
hospi[INVESTIGATOR_307]. Added footnote m to 
specify that these laboratory tests 
should be collected more frequently 
if clinically indicated. Removed 
BNP assessment.
Also, stated in Section 8.3 that 
“Safety , CRP, PK, 
pharmacodynamic, and correlative 
laborato ry tests are considered 
Tier [ADDRESS_1283521] follow the SoA.”Patient centricity; reduce 
amount of blood 
collectionSubstantial
Clinical Study Protocol -5.0 [COMPANY_008]
Acalabrutinib -D822FC00003
CONFIDENTIAL AND PROPRIETARY 97of 103Section number and 
nameDescription of change Brief rationaleSubstantial/ 
non-substantial
1.1 Schedule of 
Activities (Table 1);
8.[ADDRESS_1283522] is discharged prior to 
Day 7 (+ 3 days) (instead of 
Day 10), he/she needs to visit the 
site for an assessment [ADDRESS_1283523] 
in isolatio n due to 
COVID -19Non-substantial
1.1 Schedule of 
Activities (Table 1);
8.4.[ADDRESS_1283524] should not be performed.Patient centricity, since 
taking arterial gases is 
painful Non-substantial
1.2 Synopsis;
2.1 Background and 
Study RationaleCited recent publications reporting 
activity  of acalabrutinib and other 
Btk inhibitors in COVID -19 Clarification Non-substantial
1.2 Synopsis;
3 Objectives and 
EndpointsReduced the number of PK 
parameters to be assessed for the PK 
endpointGiven the reduced 
number of plasma 
samples for PKNon-substantial
1.2 Synopsis;
6.1 Treatments 
administeredRevised Section 6. 1 and 
restructured with sub -headers for 
clarity . Aligned Sections 1.2 and 
6.1.Clarification Non-substantial
Added text to Section [IP_ADDRESS] to 
indicate that subjects on 
concomitant PPIs must take 
acalab rutinib with 8 ounces 
(approximately 240 mL) of COCA -
COLA at room temperature. Other 
cola beverages are not permitted. Based on new data 
generated by [CONTACT_913402] [INVESTIGATOR_913356] -5.0 [COMPANY_008]
Acalabrutinib -D822FC00003
CONFIDENTIAL AND PROPRIETARY 98of 103Section number and 
nameDescription of change Brief rationaleSubstantial/ 
non-substantial
4.5 End of Study 
Definitio n;
7.1 Discontinuation of 
Study Treatment;
8.6.2 Time Period and 
Frequency for 
Collecting AE and 
SAE Information;
9.6.1 Safety AnalysesSpecified that safety follow -up will 
occur 38 (± 3 days) after 
randomization for those subjects 
randomized to the BSC armClarification Non-substantial
5.1 Inclusion Criteria Inclusion Criterion 3: Revised to 
indicate that SARS -CoV-[ADDRESS_1283525] be confirmed within 7 days 
(instead of 3 days) prior to 
randomizationPatient centr icity and 
given lack of RT -PCR 
resources in local 
hospi[INVESTIGATOR_913357]-substantial
5.2 Exclusion Criteria Exclusion Criterion 8: Changed 
“within 24 hours at screening” to 
“during the screening period”To align with revised 
screening period of 1 to 3 
daysNon-substantial
Exclusion Criterion 16: Revised 
hepatitis serology criteriaClarification Non-substantial
Exclusion Criterion 1 9: Removed 
PPI [INVESTIGATOR_913358] 1 9: Revised 
immunomodulatory/ 
immunosuppressive treatment 
exclusion Clarification Non-substantial
Exclusion Criterion 21: Removed 
steroid restrictionAlign with global 
treatment practicesSubstantial
6.1 Treatments 
Administered;
6.7Dose Modification 
and Toxicity 
ManagementAdded text to allow participants to 
make up missed doses Allow participants to 
receive the full dosing of 
acalab rutinib (total of 
20doses)Substantial
[IP_ADDRESS] Methods for 
Assigning Treatment 
GroupsRem oved the sentence, “Subjects 
will be identified to the IRT per 
country regulations.”Not applicable as only 
year of birth and gender 
are collected in the IRT 
(no full date of birth or 
initials)Non-substantial
6.5.2 Permitted 
Concomitant TherapyClarified BSC agents that will be 
permitted in this studyAlign with global 
treatment practicesSubstantial
Clinical Study Protocol -5.0 [COMPANY_008]
Acalabrutinib -D822FC00003
CONFIDENTIAL AND PROPRIETARY 99of 103Section number and 
nameDescription of change Brief rationaleSubstantial/ 
non-substantial
6.5.3 Prohibited or 
Restricted 
Concomitant TherapyClarified that certain anticoagulants 
such as warfarin or equivalent 
vitamin K antagonists (eg, 
phenprocoumon) are prohibited for 
all subjects treated with 
acalab rutinibClarification Non-substantial
Rem oved PPIs as a prohibited 
concomitant medicationBased on new data 
generated by [CONTACT_913403] a prohibited 
concomitant medicationSubstantial
Rem oved steroid treatment 
languageAlign with global 
treatment practicesSubstantial
Clarified that immunomodulatory 
drugs, intended as treatment for 
COVID -[ADDRESS_1283526] of care according to local 
institutional guidelines ,are 
prohibited for all randomized 
subjects in the study through Day 
28. Subjects who are taking 
immunomodulatory drugs for other 
medical conditions (eg, tocilizumab 
for rheumatoid arthritis) may 
continue with treatment upon 
discussion with the Medical 
Mon itor.Clarification Non-substantial
6.5.4 Acalabrutinib 
Drug -drug Interaction 
Guidance in the 
Presence of Life -
threatening COVID -19 
Infection;
[IP_ADDRESS] Active 
Substances That May 
Decrease Acalabrutinib 
Plasma Co ncentrationsAdded PPIs to Table [ADDRESS_1283527] be administered with 240 mL 
of COCA -COLA to improve 
acalab rutinib absorption.Based on new data 
generated by [CONTACT_913403] a prohibited 
concomitant medicationSubstantial
[IP_ADDRESS] Active 
Substances That May 
Decrease Acalabrutinib 
Plasma 
Concentrations;
Appendix E Examples 
of Coadministered Rem oved ranitidine Rem oved from market Non-substantial
Clinical Study Protocol -5.0 [COMPANY_008]
Acalabrutinib -D822FC00003
CONFIDENTIAL AND PROPRIETARY 100of 103Section number and 
nameDescription of change Brief rationaleSubstantial/ 
non-substantial
Drugs That Need 
Additional 
Consideration 
(Table 8)
6.6 Risks Associated 
with AcalabrutinibClarified the risks associated with 
acalab rutinib and added a table 
showing f requency  and time to 
onset of risks associated w ith 
acalab rutinibClarification Non-substantial
8.1.8 Laboratory Tests;
8.3 On -study 
ProceduresRem oved wording “(at select 
centers only)” and “(at ALL 
centers)” for the exploratory 
samples. 
Made additional changes to these 
sections for clarity and to al ign with 
the SoA.Clarification; all centers 
must collect the samplesNon-substantial
8.6.4 Adverse Event 
Data Collection;
B6 Intensity Rating 
ScaleProvided full URL for CTCAE 
V5.0Correction Non-substantial
10 References Updated references using EndNote Consistency with 
protocol templateNon-substantial
A7 Data Quality 
AssuranceChanged “source data verification” 
to “source data review”Correction Non-substantial
AE = adverse event; anti-HBc = hepatitis B core antibody; aPTT = activated partial thromboplastin time; BNP = brain 
natriuretic peptide; BSC = best supportive care; COVID -19 = coronavirus disease 2019; CRP = C -reactive protein; 
CTCAE =Common Terminology Criteria for Adverse Events; FDA = Food and Drug Administration; HBsAg = hepatitis 
Bsurface antigen; HCV = hepatitis C virus; ICU = intensive care unit; INR =international normalized ratio; IRT = 
interactive response technology; PBMC = peripheral blood mononuclear cell; PK=pharmacokinetics; PPI = proton -pump 
inhibitor; PT =prothrombi n; RT -PCR = reverse transcriptase -polymerase chain reaction; SARS -CoV-2=severe acute 
respi[INVESTIGATOR_6507] 2; SoA = Schedule of Activities; WHO = World Health Organization.
Amendment 2 (13May2020) 
Changes were implemented in the protocol amendment to address the FDA comments.
Section # and Name [CONTACT_23688]
5.2 Exclusion Criteria Revised Exclusion Criterion 23 to 
indicate that subjects who require or are 
receiving anticoagulation with warfarin 
or equivalent vitamin K antagonists (eg, 
phenprocoumon) within 7 days prior to 
randomization are excluded. Also, added 
that other anticoagulants are permitted.Revised based on FDA feedback
Clinical Study Protocol -5.0 [COMPANY_008]
Acalabrutinib -D822FC00003
CONFIDENTIAL AND PROPRIETARY 101of 103Section # and Name [CONTACT_913404] 24 to 
indicate that subjects on combined 
antiplate let and therapeutic anticoagulant 
therapy  (eg, aspi[INVESTIGATOR_913359]) at study 
entry  will be excluded
6.5.[ADDRESS_1283528] prohibition 
of anticoagulants for all subjects in both 
treatment arms. Also, clarified that 
subjects who require prophylaxis or 
therapeutic anticoagulation for 
thrombosis (deep vein thrombosis or 
pulmo nary embolism) will be allowed to 
receive therapeutic anticoagulation with a 
non-vitamin K inhibitor class of 
anticoagulants. Should subjects require 
either a vitamin K antagonist or 
combined administration of antiplatelet 
and therapeutic anticoagulation while on 
study, acalabru tinib treatment must be 
discontinued.Revised based on FDA feedback
Amendment 1 (08May2020) 
Changes were implemented in the protocol amendment to address the FDA comments.
Section # and Name [CONTACT_23688]
1.1 Schedule of Activities Added serum ferritin and CRP 
assessments at “Day 10 or discharge”To align with endpoints
1.1 Schedule of Activities;
1.2 Synopsis;
3 Objectives and Endpoints;
8.8.[ADDRESS_1283529] 2 points (from randomization) on 
a 9-point o rdinal scale through Day 28To collect additional data
1.2 Synopsis;
3 Objectives and Endpoints;
9.2 Sample Size 
Determination;
9.6.2 Efficacy AnalysesRevised the prima ry efficacy  endpoint 
of respi[INVESTIGATOR_913360] 14 to 
Day 28, and revised the secondary 
efficacy endpoint of respi[INVESTIGATOR_913361] 28 to Day 14Revised based on FDA feedback
1.2 Synopsis;
9.6.2 Efficacy Analyses;
10 ReferencesChanged method f or calculating 
confidence intervals from Blyth -Still-
Casella to Wald method with 
continuity correctionRevised based on FDA feedback
4.4 Internal DMC Specified that enrollment also be 
paused and safety reviewed upon the Added based on FDA feedback
Clinical Study Protocol -5.0 [COMPANY_008]
Acalabrutinib -D822FC00003
CONFIDENTIAL AND PROPRIETARY 102of 103Section # and Name [CONTACT_913405] 4 
hemo rrhage due to acalabrutinib (per 
Investigator)
5.2 Exclusion Criteria Exclusion Criterion 17: Added a new 
criterion to exclude subjects with 
known active HIV with detectable 
viral load or CD4 count of 
<500 cells/mm3 Added based on FDA feedback
Exclusion Criterion 18: Revised to 
exclude subjects on CYP3A inhibitor 
within 7 days (instead of 14 days) and 
inducer within 14 days (instead of 7 
days) before first dose of study drugCorrected error
Exclusion Criterion 24: Added a new 
criterion to exclude subjects on 
combined antiplatelet and 
anticoagulant therapyAdded based on FDA feedback
Clinical Study Protocol -5.0 [COMPANY_008]
Acalabrutinib -D822FC00003
CONFIDENTIAL AND PROPRIETARY 103of 103Section # and Name [CONTACT_23688]
6.5.3 Pro hibited o r Restricted 
Concomitant TherapyMoved paragraphs for strong CYP3A 
inhibito rs/inducers and proton -pump 
inhibito rs from Section [IP_ADDRESS] 
(Medications Prohibited for Subjects 
Treated with Acalabrutinib) to 
Section [IP_ADDRESS] (Medications 
Prohibited for All Randomized 
Subject)Revised based FDA feedback that 
SoC be consistent across the 
treatment arms 
[IP_ADDRESS] Medications 
Prohib ited for All 
Randomized SubjectsClarified in Section [IP_ADDRESS] that 
immunomodulatory drugs are 
prohibited for all subjects in both 
treatment arms through Day 28 and 
strong CYP3A inhibitors or inducers, 
PPIs, and steroids are prohibited for 
all subjects in both treatment arms 
through Day 10Revised based on FDA feedback
In the steroids paragraph, specified 
that if corticosteroids exceeding 7.5 
mg/day  or active inhaled 
corticosteroids are required for 
clinical care, acalabrutinib treatment 
must be discontin uedRevised based on FDA feedback
6.6 Risks Associated with 
AcalabrutinibRevised to align with updated 
Section 6.7Consistency
6.7 Dose Modification and 
Toxicity ManagementIn the table, revised event criteria and 
dose modification/discontinuation 
guidelines. Revised based on FDA feedback 
and for clarity
8.1.8 Laboratory Tests;
8.3 On -study ProceduresRem oved reference to “(at select 
centers only)” and “(at all centers)” 
from central laboratory testsRevised so that all these tests are 
required at all sites
9.6.2 Efficacy Analyses Included baseline respi[INVESTIGATOR_1399] 
(with vs without) in the subgroup 
analy sisAdded based on FDA feedback
Revised to indicate number of days in 
ICU from randomization to 90 days 
(instead of 28 days) after 
randomizationCorrected error
F1 Female Subjects of 
Childbearing PotentialRem oved prednisone, vincristine, 
doxorubicin, rituximab, and 
cyclophosphamide from the drug 
washout period Not rel evant to this study